Top

Elias Jabbour, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Jabbour

Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; and 5) triple therapy in AML. This research has also provided insight into the biology of leukemias. He has extensively addressed the question of resistance to tyrosine kinase inhibitors and to analyze the outcome of these patients. We have identified different mechanisms of resistance and described the clinical significance of them. This has clinical significance in establishing new milestones and leading to personalized therapy. This has tremendous consequences at the scientific and financial levels. He was also actively associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval of these agents for frontline CML therapy in 2010. In addition we have recently addressed the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Identifying patients at risk and applying earlier intervention may significantly improve their prognosis. He is leading our efforts to test triple therapy in AML (nucleoside analogs + anthracyclines + cytarabine). The interim results from this randomized trial show a significant improvement in outcome in patients who receive the nucleoside analog clofarabine. This may change the standard of care for the management of patients with AML. Furthermore, I am currently investigating the benefit of adding humanized monoclonal antibody for the treatment of patients with ALL (ofatumumab and HCVAD) and collaborating in the development of monoclonal antibody studies in adult ALL. Finally, he has authored or co-authored hundreds of peer reviewed medical publications and have served on editorial boards of several scientific journals.

Meet Elias Jabbour, M.D.

In the News

ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia

Illustration of acute myeloid leukemia cells with red blood cells.

ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias

illustration with medicine bottle on blue background with pills falling out

Maintenance therapy for chronic leukemia: What patients should know

Photo of leukemia specialist Elias Jabbour, M.D., at his computer.

Chronic versus acute leukemia: Different diagnoses, different treatments

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Leukemia, MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2005	Saint Joseph University School of Medicine, Beirut, LB, Hematology-Oncology, Fellow, Specialty Diploma
2003	University of Paris V School of Medicine, Paris, FR, Hematology (Clinic and Biologic Options), University Diploma
2002	University of Paris XI School of Medicine, Paris, FR, Clinical Carcinology, University Diploma
1999	Educational Committee for Foreign Medical Graduates, Philadelphia, Pennsylvania, US, MD, Certificate
1999	Saint Joseph University, Beirut, LB, Biologic Sciences, Masters
1998	Saint Joseph University, Beirut, LB, MD

Postgraduate Training

2005-2007	Clinical Fellowship, Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas
2003-2005	Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
2001-2003	Clinical Fellowship, Hematology-Oncology, Gustave Roussy Institute, Villejiuf
1998-2001	Clinical Residency, Saint Joseph University, Beirut

Board Certifications

2017	American Board of Medical Oncology
2016	American Board of Internal Medicine
2010	Lebanese Board of Hematology
2010	Lebanese Board of Oncology

Experience & Service

Academic Appointments

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2012

Administrative Appointments/Responsibilities

Section Chief, Acute Lymphocytic Leukemia, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present

Other Appointments/Responsibilities

Member, Integrated Clinical Team, Houston, TX, 2014 - 2016

Member, MDA Faculty Senate, Houston, TX, 2011 - 2017

Member, Clinical Research Committee, Houston, TX, 2010 - 2016

Institutional Committee Activities

Chair, Clinical Faculty Review Committee, 2023 - Present

Faculty Senate, Executive Billing Compliance Committee, 2021 - Present

Clinician - Executive Committee of Faculty Senate, Executive Committee of the Faculty Senate, 2021 - 2022

Member, Clinical Faculty Review Committee, 2021 - Present

Member, Integrated Clinical Team -EPIC, 2016 - 2016

Member, Conflict of Interest Committee, 2015 - Present

Member, MDA Faculty Advisory Board, 2011 - Present

Committee Member, Clinical Research Committee (CRC), 2010 - 2016

Honors & Awards

2023	Ben Qurrah Award, National Arab American Medical Association
2022	Presidential Lebanese Order of Merit Award
2022	King Hussein Lifetime Achievement Award for Cancer Research
2021	2018 Faculty Scholar Award, MDACC
2021	D.B. Lane Cancer Research Fund Distinguished Professorship in Leukemia Research, D.B. Lane Cancer Research Fund
2020	2020 Faculty Achievement Award in Patient Care, MDACC
2020	2018 Faculty Scholar Award, MDACC
2019	2018 Faculty Scholar Award, MDACC
2019	2019 ALL Team Award
2018	2018 Faculty Scholar Award, MDACC
2016	Celgene 2016 Young Investigator Award, Celgene Corporation
2007	Merit Award, American Society of Clinical Oncology
2007	The Celgene Future Leader in Hematology Award
2007	Merit Award, American Society of Hematology
2007	The Shannon Timmins Fellowship for Leukemia Research Award
2007	The Kimberly Patterson Fellowship in Leukemia Research Award
2006	Merit Award, American Society of Clinical Oncology
2006	Merit Award, American Society of Hematology
2006	Merit Award, American Society of Blood and Marrow Transplantation
2005	Merit Award, American Society of Hematology
2005	Merit Award, American Society of Clinical Oncology

Professional Memberships

Society of Hematologic Oncology

Member, 2014 - Present

American Society of Hematology

Member, 2002 - Present

Selected Publications

Peer-Reviewed Articles

Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yoshimura S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic D. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nature communications 15(1):3681, 2024. PMID: 38693155.
Jabbour, EJ, Kantarjian, HM. Chronic myeloid leukemia. American journal of hematology 99(11):2191-2212, 2024. PMID: 39093014.
Braish JS, Kugler E, Jabbour E, Woodman K, Ravandi F, Nicholas S, Jain N, Kantarjian H, Sasaki K. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(11):783-788, 2024. PMID: 39013740.
Yoshimura S, Li Z, Gocho Y, Yang W, Crews KR, Lee SHR, Roberts KG, Mullighan CG, Relling MV, Yu J, Yeoh AEJ, Loh ML, Saygin C, Litzow MR, Jeha S, Karol SE, Inaba H, Pui CH, Konopleva M, Jain N, Stock W, Paietta E, Jabbour E, Kornblau SM, Evans WE, Yang JJ. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 42(29):3478-3490, 2024. PMID: 39102629.
Haddad, FG, Sasaki, K, Nasr, L, Short, NJ, Kadia, TM, Dellasala, S, Cortes, JE, Nicolini, F, Issa, GC, Jabbour, EJ, Kantarjian, HM. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer 130(19):3344-3352, 2024. PMID: 38804723.
Senapati, J, Kantarjian, HM, Bazinet, A, Reville, PK, Short, NJ, Daver, N, Borthakur, G, Bataller, A, Jabbour, EJ, DiNardo, C, Haddad, FG, Sasaki, K, Popat, UR, Oran, B, Alousi, AM, Loghavi, S, Shpall, E, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. PMID: 38809547.
Ali, MA, Aiman, W, Kantarjian, HM, Jabbour, EJ, Ravandi-Kashani, F, Jain, N, Short, NJ, Sasaki, K. Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(10):e376-e384, 2024. PMID: 38972767.
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A, Konopleva M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer 5(10):1515-1533, 2024. PMID: 39300320.
Rahman ZA, Othman T, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther None(None):None, 2024. PMID: 39332807.
Ravandi F, Senapati J, Jain N, Short NJ, Kadia T, Borthakur G, Konopleva M, Wierda W, Huang X, Maiti A, Issa G, Balkin H, Garris R, Ferrajoli A, Garcia-Manero G, Alvarado Y, Kebriaei P, Jabbour E, Kantarjian HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia None(None):None, 2024. PMID: 39322712.
Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, Abbas H, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol None(None):None, 2024. PMID: 39303729.
Sasaki, K, Kantarjian, HM, Montalban Bravo, G, Hammond, DE, Jabbour, EJ, Kanagal Shamanna, R, Chien, KS, Garcia-Manero, G. Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 24(9):629-633, 2024. PMID: 38777652.
Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. PMID: 38591430.
Akiyama, H, Kantarjian, HM, Jabbour, EJ, Issa, GC, Haddad, FG, Short, NJ, Hu, S, Ishizawa, J, Andreeff, M, Sasaki, K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. International journal of hematology 120(2):203-211, 2024. PMID: 38748089.
Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, Kanagal-Shamanna R, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Garris R, Nasnas C, Nasr L, Ravandi F, Jabbour E. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol None(None):JCO2400272, 2024. PMID: 39028925.
Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract None(None):OP2400027, 2024. PMID: 39013130.
Montalban-Bravo G, Jabbour E, Chien K, Hammond D, Short N, Ravandi F, Konopleva M, Borthakur G, Daver N, Kanagal-Shammana R, Loghavi S, Qiao W, Huang X, Schneider H, Meyer M, Kantarjian H, Garcia-Manero G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leukemia Research 142:107518, 2024. PMID: 38744144.
Haddad FG, Nasnas C, Sasaki K, Paul S, Issa GC, Rausch C, Jabbour E, Kantarjian H. Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clinical Lymphoma, Myeloma and Leukemia 24(7):484-487, 2024. PMID: 38503634.
Zhao Y, Laird AD, Roberts KG, Yafawi RL, Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Cassaday RD, Loyd MR, Olsen SR, Neale GA, Liu X, Vandendries E, Advani AS, Mullighan CG. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Advances 8(12):3226-3236, 2024. PMID: 38607410.
Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gómez-Almaguer D, Baer MR, Gambacorti-Passerini C, McCloskey J, Minami Y, Papayannidis C, Rocha V, Rousselot P, Vachhani P, Wang ES, Wang B, Hennessy M, Vorog A, Patel N, Yeh T, Ribera JM. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA 331(21):1814-1823, 2024. PMID: 38722621.
Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian H. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(6):375-381, 2024. PMID: 38431521.
Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. PMID: 38804782.
Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Sasaki K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?. Leukemia 38(5):947-950, 2024. PMID: 38531949.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation. American journal of hematology 99(5):836-843, 2024. PMID: 38400519.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. Journal of Clinical Oncology 42(13):1499-1508, 2024. PMID: 38277619.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. e-Pub 2024. PMID: 38695144.
Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz MT, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas JM, Gordon PR, Brüggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. American journal of hematology 99(4):586-595, 2024. PMID: 38317420.
Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clinical Cancer Research 30(7):1319-1326, 2024. PMID: 38300723.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology 11(4):e287-e298, 2024. PMID: 38548404.
Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(4):e168-e173, 2024. PMID: 38212207.
Hu S, Jabbour E, Hu CY, Tang G, Wang W, Medeiros LJ, Bueso-Ramos C. Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive?B-ALL and pose a diagnostic challenge. American journal of hematology 99(4):721-726, 2024. PMID: 38240333.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology 11(4):e276-e286, 2024. PMID: 38452788.
Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, Bhatara S, Yang X, Yoshimura S, Yang W, Karol SE, Inaba H, Mullighan C, Litzow M, Zhu X, Zhang Y, Stock W, Jain N, Jabbour E, Kornblau SM, Konopleva M, Pui CH, Paietta E, Evans W, Yu J, Yang JJ. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell 42(4):552-567.e6, 2024. PMID: 38593781.
Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol. e-Pub 2024. PMID: 38607091.
Klink AJ, Keating SJ, Brokars J, Feinberg B, Jabbour E. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(3):149-157, 2024. PMID: 38135632.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. British Journal of Haematology 204(3):898-909, 2024. PMID: 37946611.
Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X, Kantarjian H. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38(3):475-481, 2024. PMID: 38287132.
Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. The Lancet Haematology 11(3):e186-e195, 2024. PMID: 38316133.
Helou M, Nasr J, Hajjar M, Bourji A, Feghaly R, Jabbour E, Abboud E, Abboud E, Mahdi A, Mina J, Asmar A, Husni R. Epidemiology of pathogens causing acute diarrhea in patients presenting to the emergency departments in 4 hospitals in Lebanon. Medicine (Baltimore) 103(9):e37316, 2024. PMID: 38428867.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour E, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. e-Pub 2024. PMID: 38551807.
Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Advances 8(4):909-915, 2024. PMID: 38207208.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour E, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Advances 8(4):927-935, 2024. PMID: 38113472.
Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission. Blood 143(5):417-421, 2024. PMID: 37879077.
Rivera D, Cui W, Gao J, Peker D, Zhang QY, Dewar R, Qiu L, Konoplev S, Hu Z, Sasaki K, Hu AY, E S, Liu M, Fang H, Wang W, Tang G, Apperley JF, Hochhaus A, Cortes JE, Khoury JD, Medeiros LJ, Jabbour E, Hu S. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: a Report From the BCR::ABL1 Pathology Group. Modern Pathology 37(2):100406, 2024. PMID: 38104892.
Jabbour E, Patel S, Lacroix G, Pechlivanoglou P, Shah PS, Beltempo M, Network Investigators CPBNICN. Validation of a Costing Algorithm and Cost Drivers for Neonates admitted to the Neonatal Intensive Care Unit. Am J Perinatol. e-Pub 2024. PMID: 38262468.
Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Monovich AC, Narina S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Pruett-Miller SM, Ryan RJH, Yang JJ, Evans WE, Savic D. Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. Cell Genomics 3(12):100442, 2023. PMID: 38116118.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of Hematology and Oncology 16(1):73, 2023. PMID: 37422688.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour E, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia. Blood cancer journal 13(1):101, 2023. PMID: 37386016.
Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. Journal of Hematology and Oncology 16(1):44, 2023. PMID: 37131217.
Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer 129(23):3805-3814, 2023. PMID: 37769040.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour E, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. medRxiv, 2023. e-Pub 2023. PMID: 38106221.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. PMID: 37608562.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. American journal of hematology 98(11):1711-1720, 2023. PMID: 37635400.
Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades. Clinical Lymphoma, Myeloma and Leukemia 23(11):e369-e378, 2023. PMID: 37690903.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clinical Cancer Research 29(21):4352-4360, 2023. PMID: 37585491.
Krug B, Hu B, Chen H, Ptack A, Chen X, Gretarsson K, Deshmukh S, Kabir N, Andrade AF, Jabbour E, Harutyunan A, Lee J, Hulswit M, Faury D, Russo C, Xu X, Johnston M, Baguette A, Dahl N, Weil A, Ellezam B, Dali R, Blanchette M, Wilson K, Garcia B, Soni RK, Gallo M, Taylor MD, Kleinman CL, Majewski J, Jabado N, Lu C. H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs. None, 2023. PMID: 38116029.
Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 23(10):742-748, 2023. PMID: 37308342.
Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. American journal of hematology 98(10):1619-1626, 2023. PMID: 37485584.
Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone marrow transplantation 58(9):1000-1007, 2023. PMID: 37198234.
Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. American journal of hematology 98(9):1383-1393, 2023. PMID: 37334870.
Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. American journal of hematology 98(8):1196-1203, 2023. PMID: 37183966.
Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour E, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Advances 7(14):3573-3581, 2023. PMID: 37104058.
Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Advances 7(13):3284-3296, 2023. PMID: 36884300.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour E, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood cancer discovery 4(4):276-293, 2023. PMID: 37102976.
Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Yang JJ, Evans WE, Savic D. Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures. bioRxiv, 2023. e-Pub 2023. PMID: 36824825.
Haddad FG, Kantarjian HM, Bidikian A, Jabbour E, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer 129(12):1866-1872, 2023. PMID: 36882573.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour E, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. PMID: 36892949.
El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. PMID: 36933995.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia. The Lancet Haematology 10(6):e433-e444, 2023. PMID: 37187201.
Jabbour E, Sabbagh J, Koyess E, Feghali M. Comparison of Three Activating Methods of Irrigation on Smear Layer- and Debris-Removal Efficiency After WaveOne Gold® Single File. Acta Inform Med 31(2):131-136, 2023. PMID: 37719232.
Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol 98(6):E142-E144, 2023. e-Pub 2023. PMID: 36877196.
Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. PMID: 37196217.
Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour E, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. PMID: 36715486.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. American journal of hematology 98(4):658-665, 2023. PMID: 36683287.
Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic Myeloid Leukemia Without Major Molecular Response After 2 Years of Treatment with Tyrosine Kinase Inhibitor. American journal of hematology 98(4):639-644, 2023. PMID: 36606715.
Rausch K, Kantarjian H, Jabbour E. SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches. Clin Lymphoma Myeloma Leuk 23(4):238-243, 2023. e-Pub 2023. PMID: 36872149.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Advances 7(6):933-942, 2023. PMID: 36322818.
Shuai W, Zuo Z, Li N, Garces S, Jelloul FZ, Ok CY, Li S, Xu J, You MJ, Wang W, Rehder C, Jabbour E, Patel KP, Medeiros LJ, Yin CC. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. Cancer 129(6):878-889, 2023. PMID: 36583229.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia. American journal of hematology 98(3):493-501, 2023. PMID: 36600670.
Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):746-749, 2023. e-Pub 2023. PMID: 36657414.
Abbas H, Sun H, Pierce S, Kangal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo, Jabbour E, Konopleva M, Short N, DiNardo C, Daver N, Ravandi F, Kadia T. Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. Blood Advances 14(7):828-831, 2023. PMID: None.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour E, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. PMID: 36458426.
Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour E, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 129(4):580-589, 2023. PMID: 36448227.
Sawyers JD, Jammal NJ, Short NJ, Kantarjian H, Jabbour E. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clinical Advances in Hematology and Oncology 21(2):68-75, 2023. PMID: 36780472.
Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic D. Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. medRxiv, 2023. e-Pub 2023. PMID: 36798219.
Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq, 2023. e-Pub 2023. PMID: 36865338.
Marx KR, Rausch CR, Lovell AR, Short NJ, Paul S, Jain N, Lee J, Savoy JM, Ravandi F, Jabbour E. Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals. Leukemia and Lymphoma 64(1):79-86, 2023. PMID: 36222579.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Haematology 10(1):e24-e34, 2023. PMID: 36402146.
Ye MT, Wang Y, Zuo Z, Calin S, He H, Tang Z, Jabbour E, Borthakur G, Zhang Y, Yang Y, You MJ. Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia. Cancer 129(1):49-59, 2023. PMID: 36281717.
Yap, TA, Daver, N, Mahendra, M, Zhang, J, Kamiya Matsuoka, C, Meric-Bernstam, F, Kantarjian, HM, Ravandi-Kashani, F, Collins, M, Francesco, MD, Dumbrava, EE, Fu, S, Gao, S, Gay, J, Gera, S, Han, J, Hong, DS, Jabbour, EJ, Ju, Z, Karp, DD, Lodi, A, Molina, JR, Baran, N, Naing, A, Ohanian, M, Pant, S, Pemmaraju, N, Bose, P, Piha-Paul, SA, Rodon Ahnert, J, Salguero, C, Sasaki, K, Singh, A, Subbiah, V, Tsimberidou, AM, Xu, Q, Yilmaz, M, Zhang, Q, Li, Y, Bristow, C, Bhattacharjee, M, Tiziani, S, Heffernan, TP, Vellano, CP, Jones, PH, Heijnen, CJ, Kavelaars, A, Marszalek, JR, Konopleva, M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia. Nature medicine 29(1):115-126, 2023. PMID: 36658425.
Jabbour, EJ, Bobolts, LR, Spinks, TE, Geyer, MB, Ebot-Tar, VT, Haumschild, R. Payer and Provider Solutions to Utilization Management Challenges in the Management of Rare Hematologic Cancers. American Journal of Managed Care 29(Suppl 4):S51-S60, 2023. PMID: 37129958.
McCall D, Jabbour E, Roth M, Nunez C, Cuglievan B. Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. Pediatric Blood and Cancer 70(1):e29939, 2023. PMID: 36031729.
Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. American journal of hematology 97(12):1560-1567, 2022. PMID: 36087091.
Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour E, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. American journal of hematology 97(12):1599-1606, 2022. PMID: 36117258.
Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia. The Lancet Haematology 9(12):e878-e885, 2022. PMID: 36279879.
Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology 15(1):12, 2022. PMID: 35093134.
Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour E, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nature communications 13(1):2801, 2022. PMID: 35589701.
Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission. Blood 140(20):2101-2112, 2022. PMID: 35877996.
Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, Rousselot P, Shah NP, Talpaz M, Srivastava S, Ren X, Mauro M. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. American journal of hematology 97(11):1419-1426, 2022. PMID: 36054756.
Benjamin, R, Jain, N, Maus, MV, Boissel, N, Graham, C, Jozwik, A, Yallop, D, Konopleva, M, Frigault, M, Teshima, T, Kato, K, Boucaud, F, Balandraud, S, Gianella-Borradori, A, Binlich, F, Marchiq, I, Dupouy, S, Almena-Carrasco, M, Pannaux, M, Fouliard, S, Brissot, E, Mohty, M, Bonganay, L, Catt, L, Chappell, J, Cheung, G, Chu, V, Cuthill, K, Devereux, S, Dunlop, A, Ellard, R, Farzeneh, F, Folarin, N, Giemza, E, Kassam, S, Kazmi, M, Kuhnl, A, Lewis, J, Liskova, M, Mason, A, Metaxa, V, Mufti, G, Munro, H, Pagliuca, A, Patten, P, Potter, V, Jabbour, EJ, Kantarjian, HM, Kebriaei, P, Wierda, WG. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM). The Lancet Haematology 9(11):e833-e843, 2022. PMID: 36228643.
Jabbour E, Sasaki K, Haddad F, Issa G, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur B, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase. American journal of hematology 97(11):1413-1418, 2022. PMID: 36054032.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia. American journal of hematology 97(11):1443-1452, 2022. PMID: 36054614.
Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour E, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia. American journal of hematology 97(11):1427-1434, 2022. PMID: 36053747.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol, 2022. PMID: 36402146.
Issa GC, Bidikian A, Venugopal S, Konopleva MY, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SR, Takahashi K, Tang G, Loghavi S, Patel KP, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver NG. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Advances, 2022. PMID: 36322818.
Bidikian, A, Kantarjian, HM, Jabbour, EJ, Short, NJ, Ravandi-Kashani, F, Issa, GC, Sasaki, K. CML-288 Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S291, 2022. PMID: 36163917.
Haddad FG, Kantarjian H, Jabbour E. EXABS-133-ALL Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22 Suppl 2:S39-S41, 2022. PMID: 36164110.
Haddad, FG, Kantarjian, HM, Short, NJ, Konopleva, M, Jain, N, Huang, X, Ravandi-Kashani, F, Wierda, WG, Borthakur, G, Sasaki, K, Issa, GC, Alvarado, Y, Pemmaraju, N, Garcia-Manero, G, Thankachan, J, Garris, R, Jabbour, EJ. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S204, 2022. PMID: 36163747.
Apperley, JF, Kantarjian, HM, Deininger, M, Abruzzese, E, Cortes, JE, Chuah, C, DeAngelo, DJ, DiPersio, JF, Hochhaus, A, Lipton, JH, Nicolini, FE, Pinilla-Ibarz, J, Rea, D, Rosti, G, Rousselot, P, Mauro, M, Shah, NP, Talpaz, M, Vorog, A, Ren, X, Jabbour, EJ. CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials. Clinical Lymphoma, Myeloma and Leukemia 22:S284-S285, 2022. PMID: 36163903.
Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, N, Kadia, TM, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia 22:S321, 2022. PMID: 36163977.
Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, G, Garcia, JS, Bose, P, Jabbour, EJ, Ravandi-Kashani, F, Daver, N, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, DiNardo, C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S240-S241, 2022. PMID: 36163821.
Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. PMID: 36163813.
Ong, F, Kim, K, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Kadia, TM, Jabbour, EJ, Short, NJ, Hammond, DE, Pemmaraju, N, Pierce, S, Montalban Bravo, G, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH). Clinical Lymphoma, Myeloma and Leukemia 22:S319, 2022. PMID: 36163972.
Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. PMID: 36163960.
Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. PMID: 36163957.
Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. PMID: 36163817.
Baran, N, Babakhanlou, R, Sasaki, K, Takahashi, K, Short, NJ, Ravandi-Kashani, F, Garcia-Manero, G, Jabbour, EJ, Kantarjian, HM, Jain, N. ALL-346 Acute Lymphoblastic Leukemia Following Multiple Myeloma Therapy. Clinical Lymphoma, Myeloma and Leukemia 22:S201-S202, 2022. PMID: 36163741.
Bidikian, A, Kantarjian, HM, Jabbour, EJ, Short, NJ, Patel, KP, Ravandi-Kashani, F, Sasaki, K, Issa, GC. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood cancer journal 12(10), 2022. PMID: 36307398.
Kim, K, Ong, F, Montalban Bravo, G, Kanagal Shamanna, R, Kadia, TM, Jabbour, EJ, Alvarado, Y, Sasaki, K, Dong, XQ, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Chien, KS, Garcia-Manero, G. MDS-406 Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 22:S310, 2022. PMID: 36163955.
Bidikian, A, Kantarjian, HM, Dabaja, BS, Ravandi-Kashani, F, Jabbour, EJ, DiNardo, C, Borthakur, G, Daver, N, Garcia-Manero, G, Kadia, TM, Sasaki, K, Issa, GC. AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Clinical Lymphoma, Myeloma and Leukemia 22:S233-S234, 2022. PMID: 36163805.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. The Lancet Haematology 9(10):e756-e765, 2022. PMID: 36063832.
Le Blanc G, Jabbour E, Patel S, Kazantseva O, Marco Zeid M, Olivier F, Shalish W, Beltempo M. Organizational Risk Factors and Clinical Impacts of Unplanned Extubation in the Neonatal Intensive Care Unit. J Pediatr 249:14-21, 2022. PMID: 35714965.
Busque AA, Jabbour E, Patel S, É C, Garfinkle J, Khairy M, Claveau M, Beltempo M. Incidence and risk factors for autism spectrum disorder among infants born <29 weeks' gestation. Paediatr Child Health 27(6):346-352, 2022. e-Pub 2022. PMID: 36200098.
Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid 1(10):EVIDoa2200034, 2022. PMID: 38319837.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour E, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Blood 140(11):1200-1228, 2022. PMID: 35767897.
Jabbour E, Kantarjian H. Chronic myeloid leukemia. American journal of hematology 97(9):1236-1256, 2022. PMID: 35751859.
Jabbour E, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. American journal of hematology 97(9):1135-1141, 2022. PMID: 35713551.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour E, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed or Refractory AML Harboring RAS Pathway-Activating Mutations. Acta haematologica 145(5):529-536, 2022. PMID: 35717939.
Stelljes M, Advani AS, DeAngelo DJ, Wang T, Neuhof A, Vandendries E, Kantarjian H, Jabbour E. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clinical Lymphoma, Myeloma and Leukemia 22(9):e836-e843, 2022. PMID: 35643855.
Arber D, Orazi A, Hasserjian R, Borowitz M, Calvo K, Kvasnicka HM, Wang S, Bagg A, Barbui T, Branford S, Bueso-Ramos C, Cortes J, Cin P, DiNardo C, Dombret H, Duncavage E, Ebert B, Estey E, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley L, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs G, Hoffman R, Jabbour E, Kiladjian J, Larson R, Le Beau M, Loh M, Löwenberg B, Macintyre E, Malcovati L, Mullighan C, Niemeyer C, Odenike O, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich J, Reiter A, Rozman M, Rudelius M, Savona M, Schiffer C, Schmitt-Graeff A, Shimamura A, Sierra J, Stock W, Stone R, Tallman M, Thiele J, Tien HF, Tzankov A, Vannucchi A, Vyas P, Wei A, Weinberg O, Wierzbowska A, Cazzola M, Döhner H, efferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 15(140):1200-12228, 2022. PMID: 35767897.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. American journal of hematology 97(8):1035-1043, 2022. PMID: 35583199.
Stanchina M, Lincoln J, Prenda S, Holt M, Leon I, Donat W, Corrao W, Jabbour E, Koenig S, Malhotra A. The impact of different CPAP delivery approaches on nightly adherence and discontinuation rate in patients with obstructive sleep apnea. J Clin Sleep Med 18(8):2023-2027, 2022. e-Pub 2022. PMID: 35499279.
Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do K, Class K, Short N, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres M, Steensma D, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian H, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid 1, 2022. PMID: None.
Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Advances 6(13):4006-4014, 2022. PMID: 35533262.
Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour E, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD. TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia. Blood 140(1):58-72, 2022. PMID: 35390143.
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American journal of hematology 97(7):856-864, 2022. PMID: 35357036.
Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American journal of hematology 97(7):865-876, 2022. PMID: 35384048.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American journal of hematology 97(7):885-894, 2022. PMID: 35413152.
Haddad F, Kantarjian H, Issa GC, Jabbour E, Sasaki K. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma 63(7):1-4, 2022. e-Pub 2022. PMID: 35361036.
Busque A, Jabbour E, Patel S, Couture E, Garfinkle J, Khairy M, Claveau M, Beltempo M. Incidence and risk factors for autism spectrum disorder among infants born <29 weeks' gestation. Paediatr Child Health 10(27):346-352, 2022. PMID: 36200098.
Beltempo M, Wintermark P, Mohammad K, Jabbour E, Afifi J, Shivananda S, Louis D, Redpath S, Lee KS, Fajardo C, Shah PS, Network Investigators CN. Variations in practices and outcomes of neonates with hypoxic ischemic encephalopathy treated with therapeutic hypothermia across tertiary NICUs in Canada. J Perinatol 42(7):898-906, 2022. e-Pub 2022. PMID: 35552529.
García-Gutiérrez V, Breccia M, Jabbour E Mauro M, Cortes JE. A clinician perspective on the treatment on chronic myeloid leukemia in the chronic phase. J Hematol Oncol 11(15), 2022. PMID: 35818053.
Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead PE, Gu Z, Stock W, Litzow M, Rowe JM, Luger SM, Hunger SP, Ryland GL, Schmidt B, Ekert PG, Oshlack A, Grimmond SM, Rehn J, Breen J, Yeung D, White DL, Aldoss I, Jabbour E, Pui CH, Meggendorfer M, Walter W, Kern W, Haferlach T, Brady S, Zhang J, Roberts KG, Blombery P, Mullighan CG. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood 139(24):3519-3531, 2022. PMID: 35192684.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology 374, 2022. PMID: 35704787.
Carter BZ, Mak PY, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, Jabbour E, Hughes PE, Chen X, Morrow PK, Andreeff M. Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Molecular cancer therapeutics 21(6):879-889, 2022. PMID: 35364607.
Carter BZ, Mak PY, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, Jabbour E, Hughes PE, Chen X, Morrow PK, Andreeff M. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther 21(6):879-889, 2022. PMID: 35364607.
Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead PE, Gu Z, Stock W, Litzow M, Rowe JM, Luger SM, Hunger SP, Ryland GL, Schmidt B, Ekert PG, Oshlack A, Grimmond SM, Rehn J, Breen J, Yeung D, White DL, Aldoss I, Jabbour E, Pui CH, Meggendorfer M, Walter W, Kern W, Haferlach T, Brady S, Zhang J, Roberts KG, Blombery P, Mullighan CG. Enhancher retargetingof CDX2and UBTF::ATXN7L3 define a subtype of highrisk B-progenitor acute lymphoblastic leukemia. Blood 139(24), 2022. PMID: 35192684.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD. Blood Advances 6(10):3027-3035, 2022. PMID: 35061885.
Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36(5):1253-1260, 2022. PMID: 35132195.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood cancer journal 12(5):77, 2022. PMID: 35501304.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. The Lancet Haematology 9(5):e350-e360, 2022. PMID: 35483396.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmscytoid dendritic cell neoplasm treated with frontline HCVAD. Blood 6(10):3027-3035, 2022. PMID: 35061885.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer 12(5):77, 2022. PMID: 35501304.
Mukherjee A, Milton DR, Jabbour E, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma 63(4):1-9, 2022. e-Pub 2022. PMID: 35225133.
Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood 139(12):1908-1919, 2022. PMID: 34914826.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy. American journal of hematology 97(3):329-337, 2022. PMID: 34981570.
Jammal, N, Kantarjian, HM, Haddad, FG, Jabbour, EJ. Management of Acute Lymphoblastic Leukemia in Older Adults. Clinical Advances in Hematology and Oncology 20(3):161-168, 2022. PMID: 36607346.
Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab maintenance after allogenic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood 139(1908-1919), 2022. PMID: 34914826.
Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leukemia and Lymphoma 63(3):1-4, 2022. PMID: 34668451.
Haddad FG, Issa GC, Jabbour E, Yilmaz M. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. Expert opinion on pharmacotherapy 23(7):751-758, 2022. PMID: 35412404.
Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. American journal of hematology 97(1):68-78, 2022. PMID: 34716921.
Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel) 14(1), 2022. PMID: 35008312.
Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour E. The cure of leukemia through the optimist’s prism. J Hematol Oncol 15(128):240-259, 2022. PMID: 34614211.
Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. PMID: 35093134.
Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement. Blood Advances 5(23):5415-5419, 2021. PMID: 34525185.
Saxena, K, Jabbour, EJ, Issa, GC, Sasaki, K, Ravandi-Kashani, F, Maiti, A, Daver, N, Kadia, TM, DiNardo, C, Konopleva, M, Cortes, JE, Yilmaz, M, Chien, KS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. Journal of Hematology and Oncology 14(1), 2021. PMID: 34130720.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. PMID: 34007049.
Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature communications 12(1):2607, 2021. PMID: 33972549.
van Dijk AD, Hoff FW, Qiu YH, Chandra J, Jabbour E, ESJM DB, Horton TM, Kornblau SM. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clinical epigenetics 13(1):21, 2021. PMID: 33509276.
Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Ventoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel) 29(14):150, 2021. PMID: 35008312.
Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Advances 5(22):4569-4574, 2021. PMID: 34555853.
Khouri IF, Milton DR, Gulbis AM, Jabbour E, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. 9-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant. Clinical Cancer Research 27(21):5847-5856, 2021. PMID: 34380640.
Klisovic RB, Leung WH, Brugger W, Dirnberger-Hertweck M, Winderlich M, Ambarkhane SV, Jabbour E. A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia. Cancer 127(22):4190-4197, 2021. PMID: 34343354.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour E, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 127(22):4213-4220, 2021. PMID: 34343352.
Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. British Journal of Haematology 195(3):378-387, 2021. PMID: 34340254.
Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. American journal of hematology 96(11):1420-1428, 2021. PMID: 34351647.
Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica 106(11):2853-2858, 2021. PMID: 33054123.
Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson P, Jain N, Kantarjian H, Jabbour E. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma. Blood Advances 5(20):3913-3918, 2021. PMID: 34464974.
Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. PMID: 34171128.
Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127(19):3552-3565, 2021. PMID: 34161603.
Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia. Cancer 127(18):3381-3389, 2021. PMID: 34138471.
Fang H, Wang W, El Hussein S, Morita K, Beird HC, Mitra A, Loghavi S, Lin P, Jabbour E, Khoury JD. B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL. British Journal of Haematology 194(6):1034-1038, 2021. PMID: 34402058.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. PMID: 33914911.
Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood cancer journal 11(9):162, 2021. PMID: 34588432.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology 39(25):2768-2778, 2021. PMID: 34043428.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian H. Vetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. M.J Clin Oncol 1(29):2768-2778, 2021. PMID: 34043428.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Advances 5(16):3163-3173, 2021. PMID: 34424319.
Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour E, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. PMID: 33853292.
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. PMID: 33793964.
Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer 127(15):2641-2647, 2021. PMID: 33823073.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. JAMA Oncology 7(8):1213-1219, 2021. PMID: 34110383.
Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. American journal of hematology 96(8):1000-1007, 2021. PMID: 33991360.
Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American journal of hematology 96(8):914-924, 2021. PMID: 33901324.
Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma:1-9. e-Pub 2021. PMID: 34380367.
Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour E, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 1(106):2121-2130, 2021. PMID: 33853292.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Ventoclax for First-line Treatment of Chronic Lympocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. PMID: 34110383.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. The final result of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 24(5):3163-3173, 2021. PMID: 34424319.
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncology 14(1):94, 2021. PMID: None.
Sasaki, K, Ravandi-Kashani, F, Kadia, TM, DiNardo, C, Short, NJ, Borthakur, G, Jabbour, EJ, Kantarjian, HM. De novo acute myeloid leukemia. Cancer 127(12):2049-2061, 2021. PMID: 33818756.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without Blinatumomab in rlapsed/refractory Philidelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. PMID: 33740268.
Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127(11):1894-1900, 2021. PMID: 33449377.
Sasaki K, Jabbour E, Short NJ, Jain N, Ravandi F, Pui CH, Kantarjian H. Acute lymphoblastic leukemia. American journal of hematology 96(6):650-658, 2021. PMID: 33709456.
Quesada, AE, Luthra, R, Jabbour, EJ, Patel, KP, Khoury, J, Tang, Z, Alvarez, HA, Mallampati, S, Garcia-Manero, G, Montalban Bravo, G, Medeiros, LJ, Kanagal Shamanna, R. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen. Cold Spring Harbor Molecular Case Studies 7(3), 2021. PMID: 34117074.
Quesada AE, Luthra R, Jabbour E, Patel KP, Khoury JD, Tang Z, Alvarez H, Mallampati S, Garcia-Manero G, Montalban-Bravo G, Medeiros LJ, Kanagal-Shamanna R. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud 7(3), 2021. PMID: None.
Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer 127(12):2049-2061, 2021. PMID: None.
Kim K, Jabbour E, Short NJ, Kebriaei P, Kantarjian H, Ravandi F. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. Curr Oncol Rep 23(8):95, 2021. PMID: None.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clinical Lymphoma, Myeloma and Leukemia 21(5):338-344, 2021. PMID: 33597098.
Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell acute lymphoblastic leukemia/lymphoma. American journal of hematology 96(5):589-598, 2021. PMID: 33639000.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. PMID: 33846541.
Kantarjian, HM, Stock, W, Cassaday, R, DeAngelo, DJ, Jabbour, EJ, O’Brien, SM, Stelljes, M, Wang, T, Luisa Paccagnella, M, Nguyen, K, Sleight, B, Vandendries, E, Neuhof, A, Douglas Laird, A, Advani, A. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial. Clinical Cancer Research 27(10):2742-2754, 2021. PMID: 33602684.
Samra B, Kantarjian HM, Sasaki K, Alotaibi AS, Konopleva M, O'Brien S, Ferrajoli A, Garris R, Nunez CA, Kadia TM, Short NJ, Jabbour E. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta haematologica 144(3):285-292, 2021. PMID: 33238261.
Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revea;led by high-throuput single-cell genomics. Nat Commun 10(12):2823, 2021. PMID: 33972555.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients with Chronic Myeloid Leukemia with Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. PMID: 33597098.
DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukemia. Epigenetics 16(5):567-576, 2021. PMID: 32856987.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Advances 5(8):2173-2183, 2021. PMID: 33885753.
Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour E, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica 106(4):1097-1105, 2021. PMID: 33297667.
Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour E, Issa GC. Impact of leuteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica 1(106):1097-1105, 2021. PMID: None.
Stock W, Martinelli G, Stelljes M, DeAngelo DJ, Gökbuget N, Advani AS, O'Brien S, Liedtke M, Merchant AA, Cassaday RD, Wang T, Zhang H, Vandendries E, Jabbour E, Marks DI, Kantarjian HM. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer 127(6):905-913, 2021. PMID: 33231879.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour E, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia. American journal of hematology 96(3):282-291, 2021. PMID: 33264443.
Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Rowland L, Shi L, Maxwell D, Smart B, Crews K, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer 2(3):284-299, 2021. PMID: 34151288.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood cancer discovery 2(2):125-134, 2021. PMID: 33681815.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. PMID: None.
Sasaki K, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase. American journal of hematology 96(2):241-250, 2021. PMID: 33180322.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. PMID: 33119202.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discovery 11(6):1440-1453, 2021. PMID: None.
Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Stelljes M, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani AS. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research 27(10):2742-2754, 2021. PMID: None.
Yammine SD, Jabbour E. Apically Extruded Debris following Programmed Over Instrumentation of Curved Canals with Three Nickel Titanium Rotary Instruments. Eur J Dent 15(1):20-26, 2021. e-Pub 2020. PMID: 32864731.
DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics 16(5):567-576, 2021. PMID: 32856987.
Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor. Leukemia and Lymphoma 62(4):909-917, 2021. PMID: 33283580.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour E Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Advances 5(7):1876-1883, 2021. PMID: 33792630.
Pullarkat, V, Lacayo, NJ, Jabbour, EJ, Rubnitz, JE, Bajel, A, Laetsch, TW, Leonard, J, Colace, S, Khaw, SL, Fleming, SA, Mattison, R, Norris, RE, Opferman, JT, Roberts, KG, Zhao, Y, Qu, C, Badawi, M, Schmidt, M, Tong, B, Pesko, JC, Sun, Y, Ross, JA, Vishwamitra, D, Rosenwinkel, L, Kim, SY, Jacobson, A, Mullighan, CG, Alexander, TB, Stock, W. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer discovery 11(6):1440-1453, 2021. PMID: 33593877.
Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour E. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leukemia and Lymphoma 62(1):224-228, 2021. PMID: 32955970.
Jabbour E, Fütterer C, Zach S, Kälsch AI, Keese M, Rahbari NN, Krämer BK, Schwenke KG. Implantation of a peritoneal dialysis catheter in patients with ESRD using local anesthesia and Remifentanil. PLoS One 16(11):e0259351, 2021. e-Pub 2021. PMID: 34735524.
Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol 95(12):E326-E329, 2020. e-Pub 2020. PMID: 32886803.
Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma 61(12):2811-2820, 2020. PMID: 32662346.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma 61(13):3120-3127, 2020. PMID: 32755333.
Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. PMID: 33351107.
Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. PMID: 33112940.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Communications 11(1):5996, 2020. PMID: None.
Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. PMID: None.
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol 95(11):1288-1295, 2020. PMID: 32681739.
Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871-e882, 2020. e-Pub 2020. PMID: 32792304.
Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5327, 2020. PMID: 33087716.
Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood 136(15):1786-1789, 2020. PMID: 32492706.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, JJabbour E, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
Malek AE, Raad II, Jabbour E. Cancer and COVID-19. Lancet(396):1066-1067, 2020. PMID: None.
Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 12(1):2823, 2020. PMID: None.
Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol 99(11), 2020. PMID: None.
Wu L, Xia M, Sun X, Han X, Zu Y, Jabbour EJ, You MJ, Lin P, Li S, Xu J, Han H, Bueso-Ramos CE, Medeiros LJ, Qiu X, Yin CC. High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. Eur J Haematol 105(4):449-459, 2020. PMID: 32535947.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. PMID: 32896301.
El Hussein S, Patel KP, Fang H, Thakral B, Loghavi S, Kanagal-Shamanna R, Konoplev S, Jabbour EJ, Medeiros LJ, Khoury JD. Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol 44(9):1235-1243, 2020. PMID: 32590457.
Jabbour E, Kantarjian H. Management of Older Patients with Acute Lymphocytic Leukemia - Novel Treatment Strategies. Clin Lymphoma Myeloma Leuk 20 Suppl 1(None):S30-S31, 2020. PMID: 32862859.
Short NJ, Jabbour E. Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care. Clin Lymphoma Myeloma Leuk 20 Suppl 1(None):S52-S53, 2020. PMID: 32862868.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour E, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. PMID: None.
Short NJ, Jabbour E. Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care. Clin Lymphoma Myeloma Leuk 20(Suppl):52-S53, 2020. PMID: None.
Jabbour E, Kantarjian H. Management of Older Patients with Acute Lymphocytic Leukemia - Novel Treatment Strategies. Clin Lymphoma Myeloma Leuk 20(Suppl 1):S30-S31, 2020. PMID: None.
El Hussein S, Patel KP, Fang H, Thakral B, Loghavi S, Kanagal-Shamanna R, Konoplev S, Jabbour E, Medeiros LJ, Khoury JD. Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathology 44(9):1235-1243, 2020. PMID: None.
Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk 20(9):e597-e605, 2020. PMID: 32303488.
DeAngelo DJ, Advani AS, Marks DI, Stelljes M, Liedtke M, Stock W, Gokbuget N, Jabbour E, Merchant A, Wang T, Vandendries E, Neuhof A, Kantarjian H, O'Brien S. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J 10(8):81, 2020. PMID: 32769965.
Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma 61(8):1943-1953, 2020. PMID: 32264726.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma 61(13):3120-3127, 2020. PMID: None.
Cassaday RD, Marks DI, DeAngelo DJ, Jabbour E, Advani AS, O'Brien S, Wang T, Neuhof A, Vandendries E, Kantarjian HM, Stock W, Stelljes M. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol 191(3):e77-e81, 2020. PMID: None.
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol 95(11):1288-1295, 2020. PMID: None.
Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma 61(12):2811-2820, 2020. PMID: None.
Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol 95(9):E245-E247, 2020. PMID: None.
Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 191(1):e10-e13, 2020. PMID: None.
Wu L, Xia M, Sun X, Han X, Zu Y, Jabbour E, You MJ, Lin P, Li S, Xu J, Han H, Bueso-Ramos CE, Medeiros LJ, Qiu X, Yin CC. High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. Eur J Haematol 105(4):449-459, 2020. PMID: None.
Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. PMID: 32589978.
Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 95(7):734-739, 2020. PMID: 32170867.
Pandey RK, DiPippo A, Kadia T, Pemmaraju N, Workeneh BT, Jabbour E, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma 61(11):2775-2777, 2020. PMID: None.
Viardot A, Locatelli F, Stieglmaier J, Zaman F, Jabbour E. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol 99(10):2215-2229, 2020. PMID: None.
Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. e-Pub 2020. PMID: 32557828.
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95(6):691-709, 2020. e-Pub 2020. PMID: 32239758.
Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC 3rd, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J 10(5):61, 2020. PMID: 32457305.
Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. PMID: 32125707.
Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. PMID: 32324887.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. PMID: 32251497.
Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer 126(7):1448-1459, 2020. PMID: 31999850.
Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-Gonzalez GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer 126(7):1502-1511, 2020. PMID: 31999839.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. PMID: 32035785.
El Fakih R, Chaudhri N, Alfraih F, Rausch CR, Naqvi K, Jabbour E. Complexity of chronic-phase CML management after failing a second-generation TKI. Leuk Lymphoma 61(4):776-787, 2020. PMID: 31739705.
Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk 20(9):e597-e605, 2020. PMID: None.
Rausch CR, Jabbour E, Kantarjian HM, Kadia TM. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer 126(6):1152-1160, 2020. e-Pub 2019. PMID: 31794095.
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica 105(3):697-707, 2020. e-Pub 2019. PMID: 31123034.
Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer 126(4):765-774, 2020. PMID: 31742675.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. PMID: 32027746.
Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2019. PMID: 31682008.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour E, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. PMID: None.
Jabbour E, Gokbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res 88(None):106283, 2020. PMID: 31790983.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2019. PMID: 31553487.
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol 143(6):567-573, 2020. PMID: 32289808.
Jabbour EJ, Gokbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer 125(23):4181-4192, 2019. PMID: 31433496.
Rafei H, Jabbour E, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma 60(13):1-4, 2019. e-Pub 2019. PMID: 31246142.
Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma 60(13):1-9, 2019. e-Pub 2019. PMID: 31125272.
Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. PMID: 31595538.
Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol 17(12):686-696, 2019. PMID: 31851157.
Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med 8(15):6559-6565, 2019. PMID: 31502383.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour E, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Sasaki K, Kantarjian HM, Jabbour E. Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. Cancer 125(21):3891-3892, 2019. e-Pub 2019. PMID: 31291004.
Jabbour E, Mendiola MF, Lingohr-Smith M, Lin J, Makenbaeva D. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. J Med Econ 22(11):1-6, 2019. e-Pub 2019. PMID: 31074658.
Rafei H, Kantarjian HM, Jabbour E. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma 60(11):1-16, 2019. e-Pub 2019. PMID: 31092071.
Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer 125(18):3219-3224, 2019. e-Pub 2019. PMID: 31150121.
Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. PMID: 31400961.
Li N, Wang SA, Lin P, Jabbour E, Thompson P, Chen Z, Li S, Xu J, You MJ, Bueso-Ramos CE, Medeiros LJ, Yin CC. Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. Am J Hematol 94(9):1049-1051, 2019. e-Pub 2019. PMID: 30916805.
Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour E, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol 186(4):538-548, 2019. e-Pub 2019. PMID: 31115909.
Jabbour E, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer 125(14):2474-2487, 2019. e-Pub 2019. PMID: 30920645.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour E, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767-1774, 2019. e-Pub 2019. PMID: 30632841.
Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour E, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer 125(13):2233-2241, 2019. e-Pub 2019. PMID: 30861111.
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol 6(6):e317-e327, 2019. e-Pub 2019. PMID: 31060979.
Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour E, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470-1481, 2019. e-Pub 2018. PMID: 30500073.
Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour E, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
Kantarjian HM, Jabbour E, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer 125(10):1665-1673, 2019. e-Pub 2019. PMID: 30668890.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour E, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 125(7):1091-1100, 2019. e-Pub 2018. PMID: 30521114.
Mesa RA, Su Y, Woolfson A, Prchal JT, Turnbull K, Jabbour E, Scherber R, Shields AL, Krohe M, Ojo F, Pompilus F, Cappelleri JC, Harrison C. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health Qual Life Outcomes 17(1):61, 2019. e-Pub 2019. PMID: 30975150.
Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour E, Khoury JD. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica 104(4):749-755, 2019. e-Pub 2018. PMID: 30361418.
Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol 94(4):408-416, 2019. e-Pub 2019. PMID: 30623490.
Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 3(6):851-861, 2019. PMID: 30885996.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922-933, 2019. PMID: 30902805.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour E, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2018. PMID: 30635233.
Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2018. PMID: 30409776.
Jabbour E, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D. Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States. Leuk Lymphoma 60(3):668-674, 2019. e-Pub 2018. PMID: 30124372.
Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol 37(1):96-102, 2019. e-Pub 2018. PMID: 30153704.
Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2018. PMID: 30328139.
Ok CY, Medeiros LJ, Thakral B, Tang G, Jain N, Jabbour E, Pierce SA, Konoplev S. High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol 32(1):48-58, 2019. e-Pub 2018. PMID: 30181564.
Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol 27(1):33-39, 2019. e-Pub 2017. PMID: 28682832.
Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. PMID: 30501869.
Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour E, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol 93(11):1376-1383, 2018. e-Pub 2018. PMID: 30117185.
Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour E, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia 32(11):2512-2518, 2018. e-Pub 2018. PMID: 29749401.
Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med 7(11):5457-5469, 2018. e-Pub 2018. PMID: 30318751.
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103(11):e514-e518, 2018. e-Pub 2018. PMID: 29794146.
Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85, 2018. e-Pub 2018. PMID: 30245189.
Jabbour E, Pui CH, Kantarjian H. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol 4(10):1413-1420, 2018. PMID: 29931220.
Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol 93(10):1245-1253, 2018. e-Pub 2018. PMID: 30051599.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour E, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 124(20):4044-4055, 2018. e-Pub 2018. PMID: 30307611.
Hidalgo-Lopez JE, Kanagal-Shamanna R, Quesada AE, Gong Z, Wang W, Hu S, Medeiros LJ, Bassett RL, d'Orcy E, Yin CC, Cortes J, Jabbour E, Kantarjian HM, Bueso-Ramos CE. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer 124(19):3849-3855, 2018. e-Pub 2018. PMID: 30321462.
Jabbour E, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model. J Med Econ 21(10):1036-1040, 2018. e-Pub 2018. PMID: 30071761.
Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol 93(9):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
Li J, Xu J, Abruzzo LV, Tang G, Li S, You MJ, Lu G, Jabbour E, Deng Q, Bueso-Ramos CE, Medeiros LJ, Yin CC. Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget 9(76):34449, 2018. e-Pub 2018. PMID: 30344953.
Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour E, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma 59(9):1-4, 2018. e-Pub 2018. PMID: 29338567.
Loghavi S, Sui D, Wei P, Garcia-Manero G, outPierce S, Rbort MJ, Jabbour E, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2(15):1807-1816, 2018. PMID: 30054307.
Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2017. PMID: 28616864.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9(1):2670, 2018. e-Pub 2018. PMID: 29991687.
Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124(13):2758-2765, 2018. e-Pub 2018. PMID: 29660836.
Saglio G, Jabbour E. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma 59(7):1-16, 2018. e-Pub 2017. PMID: 28972424.
Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36(18):1788-1797, 2018. e-Pub 2018. PMID: 29702001.
Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59(6):1-11, 2018. e-Pub 2017. PMID: 28972430.
Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer 124(12):2534-2540, 2018. e-Pub 2018. PMID: 29645075.
Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol 107(6):689-695, 2018. e-Pub 2018. PMID: 29464484.
Kurt H, Jorgensen JL, Amin HM, Patel KP, Wang SA, Lin P, Kanagal-Shamanna R, Loghavi S, Thakral B, Khogeer HA, Jabbour E, Li S, Yin CC, Medeiros LJ, Khoury JD. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol 100(5):444-454, 2018. e-Pub 2018. PMID: 29385279.
Kantarjian HM, Su Y, Jabbour E, Bhattacharyya H, Yan E, Cappelleri JC, Marks DI. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer 124(10):2151-2160, 2018. e-Pub 2018. PMID: 29508899.
Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour E, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24(10):2304-2311, 2018. e-Pub 2018. PMID: 29476021.
Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma 59(4):1-4, 2018. e-Pub 2017. PMID: 28838278.
Jabbour E, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer 124(8):1722-1732, 2018. e-Pub 2018. PMID: 29381191.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28718728.
Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM. Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18(4):257-265, 2018. e-Pub 2018. PMID: 29519619.
Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol 5(4):e136-e146, 2018. e-Pub 2018. PMID: 29550383.
Montalban-Bravo G, Garcia-Manero G, Jabbour E. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Curr Opin Hematol 25(2):146-153, 2018. e-Pub 2017. PMID: 29266015.
Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124(6):1160-1168, 2018. e-Pub 2017. PMID: 29266206.
Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia. Am J Clin Oncol 41(3):213-217, 2018. e-Pub 2015. PMID: 26580245.
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401-407, 2018. e-Pub 2017. PMID: 29218851.
Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour E, Milton DR, Bassett RL, Vence LM, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 24(5):1011-1018, 2018. e-Pub 2017. PMID: 29246938.
Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2017. PMID: 29178361.
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol 4(2):230-234, 2018. e-Pub 2017. PMID: 28859185.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2017. PMID: 29134664.
Li J, Xu J, Abruzzo LV, Tang G, Li S, You MJ, Lu G, Jabbour E, Deng Q, Bueso-Ramos CE, Medeiros LJ, Yin CC. Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget 9(13):10987-10994, 2018. e-Pub 2017. PMID: 29541391.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour E, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241-244, 2018. e-Pub 2017. PMID: 28919634.
Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer 124(2):325-334, 2018. e-Pub 2017. PMID: 29211308.
Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour E, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget 9(8):8027-8041, 2018. e-Pub 2018. PMID: 29487712.
Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93(1):84-90, 2018. e-Pub 2017. PMID: 29027261.
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39, 2018. e-Pub 2018. PMID: 30071517.
Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour E, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31080940.
Short NJ, Kantarjian H, Jabbour E. Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer 123(24):4935-4936, 2017. e-Pub 2017. PMID: 29053172.
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience. Am J Hematol 92(12):1295-1302, 2017. e-Pub 2017. PMID: 28850699.
Abaza YM, Kadia TM, Jabbour E, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer 123(24):4851-4859, 2017. e-Pub 2017. PMID: 28841236.
Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk 17(12):897-901, 2017. e-Pub 2017. PMID: 28927784.
Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102(12):e514-e517, 2017. e-Pub 2017. PMID: 28860345.
Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour E, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123(22):4391-4402, 2017. e-Pub 2017. PMID: 28743165.
Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102(10):1661-1670, 2017. e-Pub 2017. PMID: 28659335.
Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol 18(10):1317-1326, 2017. e-Pub 2017. PMID: 28844816.
Paul S, Rausch CR, Kantarjian H, Jabbour E. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol 13(25):2233-2242, 2017. e-Pub 2017. PMID: 28776425.
Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica 102(10):1709-1717, 2017. e-Pub 2017. PMID: 28729302.
Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens. Am J Hematol 92(10):E595-E597, 2017. e-Pub 2017. PMID: 28646517.
Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol 92(9):924-928, 2017. e-Pub 2017. PMID: 28556489.
Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, Jabbour E, Bomalaski JS, Chen YP, Hsiao HH, Wang MC, Kuo CY, Chang H, Yeh SP, Cortes J, Chen LT, Chen TY. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Sci Rep 7(1):11253, 2017. e-Pub 2017. PMID: 28900115.
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. Blood 130(13):1514-1522, 2017. e-Pub 2017. PMID: 28774880.
Jabbour E, Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva D. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. J Med Econ 20(9):1-6, 2017. e-Pub 2017. PMID: 28681664.
Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma 58(9):1-6, 2017. e-Pub 2017. PMID: 28278723.
Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125-1131, 2017. e-Pub 2017. PMID: 28674026.
Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour E, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 123(16):3050-3060, 2017. e-Pub 2017. PMID: 28387922.
Khouri MR, Jabbour E, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL, Khouri IF. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant 23(8):1405-1410, 2017. e-Pub 2017. PMID: 28495642.
Kanagal-Shamanna R, Hidalgo Lopez JE, Milton DR, Kim HR, Zhao C, Zuo Z, Janania Martinez M, Stingo F, Lee J, Luthra R, Jabbour E, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Validation of the 2016 Revisions to the WHO Classification in Lower-Risk Myelodysplastic Syndrome. Am J Hematol 92(8):E168-E171, 2017. e-Pub 2017. PMID: 28456995.
Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour E, Zhang H, Sleight BJ, Vandendries ER, Marks DI. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol 4(8):e387-e398, 2017. e-Pub 2017. PMID: 28687420.
Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA. A Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients With Acute Myeloid Leukemia. Am J Hematol 92(7):660-667, 2017. e-Pub 2017. PMID: 28370201.
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv 1(17):1312-1323, 2017. e-Pub 2017. PMID: 29296774.
Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia 31(7):1654-1657, 2017. e-Pub 2017. PMID: 28400618.
Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol 28(7):1554-1559, 2017. e-Pub 2017. PMID: 28379307.
Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour E, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol 92(7):599-606, 2017. e-Pub 2017. PMID: 28370097.
Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 92(6):E114-E117, 2017. e-Pub 2017. PMID: 28295472.
Kantarjian H, Jabbour E, Topp MS. Blinatumomab for Acute Lymphoblastic Leukemia. N Engl J Med 376(23):e49, 2017. PMID: 28591537.
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 31(6):1391-1397, 2017. e-Pub 2017. PMID: 28111463.
Short NJ, Jabbour E. Yes, treatment for CML should continue indefinitely. Clin Adv Hematol Oncol 15(6):489-492, 2017. PMID: 28749909.
Salem A, Loghavi S, Tang G, Huh YO, Jabbour E, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury JD. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol 92(6):520-528, 2017. e-Pub 2017. PMID: 28253536.
Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer 123(6):994-1002, 2017. e-Pub 2017. PMID: 28094841.
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584-2587, 2017. e-Pub 2017. PMID: 28246192.
Yilmaz M, Kantarjian H, Jabbour E. Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol 15(4):266-274, 2017. PMID: 28591103.
Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol 92(3):279-285, 2017. e-Pub 2017. PMID: 28052371.
Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2016. PMID: 28003274.
Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123(4):629-637, 2017. e-Pub 2016. PMID: 27741352.
Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer 123(4):609-616, 2017. e-Pub 2016. PMID: 27763690.
Pinnix CC, Chi L, Jabbour E, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol 92(2):155-160, 2017. e-Pub 2016. PMID: 27874212.
Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood 129(5):572-581, 2017. e-Pub 2016. PMID: 27919910.
Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 123(3):426-435, 2017. e-Pub 2016. PMID: 27657543.
Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2016. PMID: 27696391.
Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2016. PMID: 27795561.
Khouri IF, Sui D, Jabbour E, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant 52(1):28-33, 2017. e-Pub 2016. PMID: 27595282.
Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2016. PMID: 27673440.
Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol 92(1):E3-E4, 2017. e-Pub 2016. PMID: 27727470.
Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2016. PMID: 27602508.
Jabbour E, Kantarjian H. Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Adv 1(3):260-264, 2016. e-Pub 2016. PMID: 29296940.
Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol 91(12):1221-1226, 2016. e-Pub 2016. PMID: 27474808.
Sasaki K, Jabbour E, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.
Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer 122(21):3336-3343, 2016. e-Pub 2016. PMID: 27509035.
Short NJ, Jabbour E. Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patients. Clin Adv Hematol Oncol 14(11):892-894, 2016. PMID: 27930640.
Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk 16(11):616-624, 2016. e-Pub 2016. PMID: 27601000.
Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer 122(22):3484-3491, 2016. e-Pub 2016. PMID: 27463065.
Huang L, Wang SA, Konoplev S, Bueso-Ramos CE, Thakral B, Miranda RN, Jabbour E, Medeiros LJ, Kanagal-Shamanna R. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. Medicine (Baltimore) 95(41):e4934, 2016. PMID: 27741105.
Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol 91(8):819-23, 2016. e-Pub 2016. PMID: 27178680.
Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol 91(8):800-5, 2016. e-Pub 2016. PMID: 27169385.
Hoehn D, Cortes JE, Medeiros LJ, Jabbour E, Hidalgo JE, Kanagal-Shamanna R, Bueso-Ramos CE. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S86-92, 2016. PMID: 27521332.
Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. Haematologica 101(8):e324-7, 2016. e-Pub 2016. PMID: 27175025.
Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504-7, 2016. e-Pub 2016. PMID: 27235138.
Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 30(7):1606-9, 2016. e-Pub 2016. PMID: 26837843.
Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA, Consortium MDS. The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes at the Time of Hypomethylating Agent Failure. Haematologica 101(6):e224-7, 2016. e-Pub 2016. PMID: 26992944.
Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol 91(4):E274-6, 2016. e-Pub 2016. PMID: 26798971.
Short NJ, Kantarjian HM, Jabbour E, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
Jabbour E, Kantarjian H. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Lancet 387(10036):2360-1, 2016. e-Pub 2016. PMID: 27080497.
Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer 122(12):1871-9, 2016. e-Pub 2016. PMID: 26990290.
Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol 173(1):114-26, 2016. e-Pub 2016. PMID: 26846160.
Huang L, Garcia-Manero G, Jabbour E, Goswami M, Routbort MJ, Medeiros LJ, Jorgensen JL, Wang SA. Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. J Clin Pathol. e-Pub 2016. PMID: 27083210.
Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, investigators OS. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol 17(4):496-508, 2016. e-Pub 2016. PMID: 26968357.
DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia 30(4):980-4, 2016. e-Pub 2015. PMID: 26228814.
Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127(15):1863-9, 2016. e-Pub 2016. PMID: 26747249.
Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-87, 2016. e-Pub 2016. PMID: 26871476.
Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R, Consortium MDS. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 30(3):649-57, 2016. e-Pub 2015. PMID: 26464171.
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk 16(3):152-62, 2016. e-Pub 2015. PMID: 26796981.
Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk 16(3):163-168.e2, 2016. e-Pub 2015. PMID: 26752456.
Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16(3):139-45, 2016. e-Pub 2015. PMID: 26775883.
Jabbour EJ. A Man With Pre-B-Cell, CD20-Negative ALL. Clin Adv Hematol Oncol 14(3 Suppl 4):10-4, 2016. PMID: 27007407.
Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172(3):392-400, 2016. e-Pub 2015. PMID: 26492205.
George B, Kantarjian H, Jabbour E, Jain N. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy 8(2):135-43, 2016. e-Pub 2016. PMID: 26780449.
Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour E, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS, Consortium MDS. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res 41:43-7, 2016. e-Pub 2015. PMID: 26777537.
Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30(2):268-73, 2016. e-Pub 2015. PMID: 26365212.
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91(2):252-65, 2016. PMID: 26799612.
Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen IM, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui CH, Gastier-Foster J, Gu Z, Reshmi S, Loh ML, Racevskis J, Tallman MS, Wiernik PH, Litzow MR, Willman CL, McPherson JD, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell 29(2):186-200, 2016. PMID: 26859458.
DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes J, Kantarjian H. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol 91(2):227-32, 2016. PMID: 26799610.
Jabbour E. Chronic myeloid leukemia: First-line drug of choice. Am J Hematol 91(1):59-66, 2016. PMID: 26769227.
Chamseddine AN, Jabbour E, Kantarjian HM, Bohannan ZS, Garcia-Manero G. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep 18(1):4, 2016. PMID: 26700507.
Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer 122(2):238-48, 2016. e-Pub 2015. PMID: 26479889.
Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour E, Garcia-Manero G, Medeiros LJ, Wang SA. Myelodysplastic Syndromes Following Therapy with Hypomethylating Agents (HMAs): Development of Acute Erythroleukemia May Not Influence Assessment of Treatment Response. Leuk Lymphoma 57(4):1-19, 2016. e-Pub 2016. PMID: 26293512.
McGarry LJ, Chen YJ, Divino V, Pokras S, Taylor CR, Munakata J, Nieset CC, Huang H, Jabbour E, Malone DC. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Curr Med Res Opin 32(2):1-11, 2016. e-Pub 2015. PMID: 26566171.
Dahl J, Marx K, Jabbour E. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol 9(4):329-34, 2016. e-Pub 2016. PMID: 26783163.
Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica 100(12):e494-5, 2015. e-Pub 2015. PMID: 26341741.
Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines. Clin Lymphoma Myeloma Leuk 15(12):797-802.e1, 2015. e-Pub 2015. PMID: 26603185.
Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour E, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39(12):1367-74, 2015. e-Pub 2015. PMID: 26547258.
Jabbour E. Use of PCR testing in chronic myeloid leukemia. Clin Adv Hematol Oncol 13(12):808-10, 2015. PMID: 27058845.
Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158-64, 2015. e-Pub 2015. PMID: 26308885.
Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894-904, 2015. e-Pub 2015. PMID: 26217876.
Vitale C, Lu X, Abderrahman B, Takahashi K, Ravandi F, Jabbour E. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. Am J Hematol 90(11):E211-2, 2015. e-Pub 2015. PMID: 26257212.
Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547-55, 2015. e-Pub 2015. PMID: 26432046.
Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Cain Z, Okoro T, Bolinder B, Patt D, Jabbour E. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting. Clin Lymphoma Myeloma Leuk 15(10):599-605, 2015. e-Pub 2015. PMID: 26208445.
Mattiuzzi G, Yilmaz M, Kantarjian H, Borthakur G, Konopleva M, Jabbour E, Brown Y, Pierce S, Cortes J. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. J Infect Chemother 21(9):663-7, 2015. e-Pub 2015. PMID: 26141814.
Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16(9):1099-110, 2015. e-Pub 2015. PMID: 26296954.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res 39(9):950-6, 2015. e-Pub 2015. PMID: 26183878.
Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk 15(9):556-62, 2015. e-Pub 2015. PMID: 26141213.
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol 16(9):1025-36, 2015. e-Pub 2015. PMID: 26234174.
Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. PMID: 26436130.
Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121(15):2517-28, 2015. e-Pub 2015. PMID: 25891003.
Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-63, 2015. e-Pub 2015. PMID: 26088933.
Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790-7, 2015. e-Pub 2015. PMID: 26124496.
Shen Q, Ouyang J, Tang G, Jabbour E, Garcia-Manero G, Routbort M, Konoplev S, Bueso-Ramos C, Medeiros LJ, Jorgensen JL, Wang SA. Flow Cytometry Immunophenotypic Findings in Chronic Myelomonocytic Leukemia and Its Utility in Monitoring Treatment Response. Eur J Haematol 95(2):168-76, 2015. e-Pub 2015. PMID: 25354960.
Bryan JC, Jabbour E. Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. Drugs Aging 32(8):623-37, 2015. PMID: 26286093.
Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-12, 2015. e-Pub 2015. PMID: 25840338.
Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol 90(8):752-3, 2015. e-Pub 2015. PMID: 25850565.
Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J 5:e333, 2015. e-Pub 2015. PMID: 26230957.
Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE. A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica 100(7):898-904, 2015. e-Pub 2015. PMID: 25887498.
Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer 121(14):2375-82, 2015. e-Pub 2015. PMID: 25809968.
Yilmaz M, Abaza Y, Jabbour E. Selecting the best frontline treatment in chronic myeloid leukemia. Curr Hematol Malig Rep 10(2):145-57, 2015. PMID: 25921387.
Jabbour EJ. An ALL patient with a t(4;11) translocation. Clin Adv Hematol Oncol 13(6 Suppl 7):12-3, 2015. PMID: 26431323.
Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res 21(12):2704-14, 2015. e-Pub 2015. PMID: 25724525.
Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125(26):4010-6, 2015. e-Pub 2015. PMID: 25999456.
Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica 100(5):653-61, 2015. e-Pub 2015. PMID: 25682595.
Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol 169(4):595-7, 2015. e-Pub 2014. PMID: 25413673.
Jabbour E, Garcia-Manero G. Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes. Leuk Lymphoma 56(5):1-26, 2015. e-Pub 2015. PMID: 25058371.
Mace ML, Dahl J, Jabbour E. Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?. Expert Opin Pharmacother 16(7):999-1007, 2015. e-Pub 2015. PMID: 25840461.
Cabrero M, Jabbour E, Ravandi F, Bohannan Z, Pierce S, Kantarjian HM, Garcia-Manero G. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up. Leuk Res 39(5):520-4, 2015. e-Pub 2015. PMID: 25828745.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186-93, 2015. e-Pub 2015. PMID: 26688093.
Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther 15(4):365-73, 2015. e-Pub 2015. PMID: 25764322.
Dahl J, Mace M, Kantarjian H, Jabbour E. Blinatumomab for the treatment of adult acute lymphoblastic leukemia. Drugs Today (Barc) 51(4):231-41, 2015. PMID: 26020065.
Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma 56(4):1-8, 2015. e-Pub 2014. PMID: 25048874.
Ohanian M, Kantarjian H, Guy D, Thomas D, Jabbour E, O'Brien S. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther 15(4):601-11, 2015. PMID: 25775418.
Jabbour E, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. Cancer 121(6):876-82, 2015. e-Pub 2014. PMID: 25410759.
Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R. A Phase 1 Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate 1 Risk Myelodysplastic Syndromes. Clin Cancer Res 21(5):985-94, 2015. e-Pub 2014. PMID: 25480830.
Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(3):171-6, 2015. e-Pub 2014. PMID: 25441108.
Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol 2(3):e118-28, 2015. e-Pub 2015. PMID: 26687797.
Poon ML, Fox PS, Samuels BI, O'Brien S, Jabbour E, Hsu Y, Gulbis A, Korbling M, Champlin R, Abruzzo LV, Bassett RL, Khouri IF. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma 56(3):1-5, 2015. e-Pub 2014. PMID: 24913509.
Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a cd22 monoclonal antibody. Am J Hematol 90(3):193-6, 2015. e-Pub 2015. PMID: 25407953.
Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F. Phase I trial of SAR103168, a novel multi-kinase inhibitor,in patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes. Leuk Lymphoma 56(2):395-400, 2015. e-Pub 2014. PMID: 24794806.
Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121(4):556-61, 2015. e-Pub 2014. PMID: 25336333.
Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II Study of Methotrexate, Vincristine, Pegylated-Asparaginase, and Dexamethasone (MOpAD) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Am J Hematol 90(2):120-4, 2015. e-Pub 2014. PMID: 25368968.
Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma 56(2):1-5, 2015. e-Pub 2014. PMID: 24844364.
Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2014. PMID: 25107338.
DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2014. PMID: 26687423.
Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour E, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 120(23):3660-8, 2014. e-Pub 2014. PMID: 25042398.
Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma 55(12):2879-86, 2014. e-Pub 2013. PMID: 23927391.
Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 167(3):356-65, 2014. e-Pub 2014. PMID: 25066676.
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 89(10):964-8, 2014. e-Pub 2014. PMID: 24990142.
Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
Tsimberidou AM, Keating MJ, Jabbour E, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):395-400.e1, 2014. e-Pub 2014. PMID: 24637132.
Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 2014. e-Pub 2014. PMID: 24953017.
Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease. Blood 124(14):2306-12, 2014. e-Pub 2014. PMID: 25145344.
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour E, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell 26(3):428-42, 2014. e-Pub 2014. PMID: 25132497.
Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 2014. e-Pub 2014. PMID: 25047979.
DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma 55(8):1925-9, 2014. e-Pub 2014. PMID: 24138309.
Quintás-Cardama A, Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk 14(4):327-334.e8, 2014. e-Pub 2014. PMID: 24594142.
Jabbour E, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 55(7):1451-62, 2014. e-Pub 2013. PMID: 24050507.
Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 28(7):1543-5, 2014. e-Pub 2014. PMID: 24487412.
Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol 89(5):509-16, 2014. e-Pub 2014. PMID: 24458781.
Jabbour E. Treating myelodysplastic syndrome when hypomethylating agents stop working. Clin Adv Hematol Oncol 12(4):257-9, 2014. PMID: 25003355.
Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol 5(2):29-34, 2014. PMID: 24688752.
Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 14(2):155-162.e1, 2014. e-Pub 2013. PMID: 24332214.
Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 2014. e-Pub 2014. PMID: 24375514.
Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk 14(2):93-7, 2014. e-Pub 2013. PMID: 24447728.
DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4):973-5, 2014. e-Pub 2013. PMID: 24157581.
Konopleva MY, Walter RB, Faderl SH, Jabbour E, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 20(8):2226-35, 2014. e-Pub 2014. PMID: 24583795.
Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89(3):282-7, 2014. PMID: 24779033.
Mathisen MS, Kantarjian HM, Jabbour E. Emerging drugs for acute lymphocytic leukemia. Expert Opin Emerg Drugs 19(1):37-50, 2014. e-Pub 2013. PMID: 24354521.
Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373-80, 2014. e-Pub 2013. PMID: 24151050.
Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123(4):494-500, 2014. e-Pub 2013. PMID: 24311723.
Jabbour E, Lipton JH. A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Clin Lymphoma Myeloma Leuk 13(6):646-56, 2013. e-Pub 2013. PMID: 24095296.
Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clin Lymphoma Myeloma Leuk 13(6):693-9, 2013. e-Pub 2013. PMID: 24060289.
Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour E, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88(12):1024-9, 2013. e-Pub 2013. PMID: 23913852.
Mathisen MS, Kantarjian H, Thomas D, O'Brien S, Jabbour E. Acute Lymphoblastic Leukemia (ALL) in Adults: Encouraging Developments on the Way to Higher Cure Rates. Leuk Lymphoma 54(12):2592-600, 2013. e-Pub 2013. PMID: 23547835.
Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 98(11):1686-8, 2013. e-Pub 2013. PMID: 23812943.
Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia. Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37(11):1440-4, 2013. e-Pub 2013. PMID: 23890523.
Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831-7, 2013. e-Pub 2013. PMID: 23760779.
Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour E, Owen K, Stockman PK, Oliver SD. Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. Clin Lymphoma Myeloma Leuk 13(5):559-67, 2013. e-Pub 2013. PMID: 23763917.
Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H. Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk 13(5):579-83, 2013. e-Pub 2013. PMID: 23763918.
Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27(10):2081-3, 2013. e-Pub 2013. PMID: 23774633.
Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clin Lymphoma Myeloma Leuk 13(5):592-6, 2013. e-Pub 2013. PMID: 23790798.
Jabbour E, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk 13(5):515-29, 2013. e-Pub 2013. PMID: 23890944.
Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 2013. e-Pub 2013. PMID: 23969309.
Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S289-94, 2013. e-Pub 2013. PMID: 23969308.
Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119(15):2728-36, 2013. e-Pub 2013. PMID: 23633004.
Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 13(4):477-84, 2013. e-Pub 2013. PMID: 23770156.
Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk 13(4):435-40, 2013. e-Pub 2013. PMID: 23763915.
Kantarjian HM, Martinelli G, Jabbour E, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A, Investigators S. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 119(14):2611-9, 2013. e-Pub 2013. PMID: 23605952.
Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. J Clin Oncol 31(20):2548-53, 2013. e-Pub 2013. PMID: 23733767.
Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121(24):4867-74, 2013. e-Pub 2013. PMID: 23620574.
Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr Virus-Induced CD30-Positive Diffuse Large B-Cell Lymphoma in a Patient With Mixed-Phenotypic Leukemia Treated With Clofarabine. Clin Lymphoma Myeloma Leuk 13(3):342-6, 2013. e-Pub 2012. PMID: 23246163.
Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk 13(3):302-6, 2013. e-Pub 2013. PMID: 23318257.
Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 88(5):365-9, 2013. e-Pub 2013. PMID: 23512829.
Quintás-Cardama A, Jabbour E. Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib. Leuk Res 37(5):487-95, 2013. e-Pub 2013. PMID: 23391518.
Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 4(2):103-17, 2013. PMID: 23610618.
Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 27(4):907-13, 2013. e-Pub 2012. PMID: 23174881.
Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintás-Cardama A. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk 13(2):139-43, 2013. e-Pub 2012. PMID: 23276886.
Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk 13(2):131-8, 2013. e-Pub 2012. PMID: 23260600.
Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma 54(4):688-98, 2013. e-Pub 2012. PMID: 22957815.
Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia 27(4):836-42, 2013. e-Pub 2012. PMID: 23135353.
Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2012. PMID: 23115106.
Jabbour E, Bixby D, Akard LP. Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia. Clin Adv Hematol Oncol 10(12 Suppl 22):1-16, 2012. PMID: 23271195.
Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol 13(11):1096-104, 2012. e-Pub 2012. PMID: 23075701.
Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 26(11):2428-31, 2012. e-Pub 2012. PMID: 22665218.
Chen L, Guérin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin 28(11):1831-9, 2012. e-Pub 2012. PMID: 23127201.
Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 120(16):3382-3, 2012. PMID: 23086624.
Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-70, 2012. e-Pub 2012. PMID: 22252728.
Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 2012. e-Pub 2012. PMID: 22282348.
Jabbour E, Mathisen MS, O'Brien S. 10 years of progress in chronic myelogenous leukemia. J Natl Compr Canc Netw 10(9):1049-53, 2012. PMID: 22956803.
Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL Inhibitors: Issues for CML Therapy. Clin Lymphoma Myeloma Leuk 12(4):223-9, 2012. e-Pub 2012. PMID: 22633166.
Jabbour E, Quintás-Cardama A. Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response. Leuk Lymphoma 53(8):1452-60, 2012. e-Pub 2012. PMID: 22273251.
Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 2012. e-Pub 2012. PMID: 22718840.
Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 2012. e-Pub 2012. PMID: 22534616.
Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-35, 2012. e-Pub 2012. PMID: 22271898.
Jabbour E, Kantarjian H, Eliasson L, Cornelison AM, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87(7):687-91, 2012. e-Pub 2012. PMID: 22473898.
Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High Risk Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 12(3):197-200, 2012. PMID: 22578814.
Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 118(12):3116-22, 2012. e-Pub 2012. PMID: 22370904.
Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol 30(18):2204-10, 2012. e-Pub 2012. PMID: 22585696.
Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 119(19):4524-6, 2012. e-Pub 2012. PMID: 22431574.
Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 13(7):927-38, 2012. PMID: 22519766.
Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 2012. e-Pub 2012. PMID: 22360602.
Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother 13(6):815-28, 2012. e-Pub 2012. PMID: 22429140.
Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 2012. e-Pub 2012. PMID: 22357140.
Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 2012. e-Pub 2012. PMID: 22228624.
Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol 87(3):317-8, 2012. e-Pub 2012. PMID: 22228403.
Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: Implications and management strategies. Cancer 118(5):1181-91, 2012. e-Pub 2011. PMID: 22038681.
Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-8, 2012. e-Pub 2011. PMID: 21751197.
Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 2012. e-Pub 2011. PMID: 22072492.
Cornelison M, Jabbour E, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol 10(1):14-24, 2012. PMID: 22244674.
Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H. Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118(23):6030-6, 2011. e-Pub 2011. PMID: 21976672.
Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE. Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?. J Clin Oncol 29(32):4260-5, 2011. e-Pub 2011. PMID: 21990394.
Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer 117(22):5085-93, 2011. e-Pub 2011. PMID: 21523765.
Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 38(5):682-92, 2011. PMID: 21943675.
Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118(16):4353-8, 2011. e-Pub 2011. PMID: 21846902.
Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?. Clin Lymphoma Myeloma Leuk 11(5):421-6, 2011. e-Pub 2011. PMID: 21831744.
Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118(17):4541-6, 2011. e-Pub 2011. PMID: 21803854.
Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am 25(5):981-95, 2011. e-Pub 2011. PMID: 22054730.
Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118(17):4690-3, 2011. e-Pub 2011. PMID: 21868570.
Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J Clin Oncol 29(23):3173-8, 2011. e-Pub 2011. PMID: 21747082.
Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol 86(7):546-9, 2011. e-Pub 2011. PMID: 21509801.
Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 118(4):899-902, 2011. e-Pub 2011. PMID: 21622644.
Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29(18):2521-7, 2011. e-Pub 2011. PMID: 21576646.
Fullmer A, Kantarjian H, Cortes J, Jabbour E. Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol 4(3):253-60, 2011. PMID: 21668392.
Cornelison AM, Welch MA, Koller C, Jabbour E. Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S111-3, 2011. e-Pub 2011. PMID: 22035739.
Quintás-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica 96(6):918-21, 2011. e-Pub 2011. PMID: 21357704.
Cornelison AM, Kantarjian H, Cortes J, Jabbour E. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S101-10, 2011. e-Pub 2011. PMID: 22035738.
Champlin R, Jabbour E, Kebriaei P, Anderlini P, Andersson B, de Lima M. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S96-S100, 2011. e-Pub 2011. PMID: 22035758.
Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117(21):5600-6, 2011. e-Pub 2011. PMID: 21467546.
Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117(9):1800-11, 2011. e-Pub 2010. PMID: 21509757.
Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol 7(5):661-72, 2011. e-Pub 2011. PMID: 21500965.
Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk 11(2):237-41, 2011. e-Pub 2011. PMID: 21575929.
Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy. Clin Cancer Res 17(7):1674-83, 2011. e-Pub 2011. PMID: 21307148.
Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 117(5):897-906, 2011. e-Pub 2010. PMID: 20945321.
Mathisen MS, Kantarjian HM, Cortes J, Jabbour E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 96(3):347-9, 2011. PMID: 21357713.
Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-7, 2011. e-Pub 2010. PMID: 21156844.
Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117(6):1236-44, 2011. e-Pub 2010. PMID: 20960519.
Fullmer A, Kantarjian H, Cortes J, Jabbour E. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma 52 Suppl 1:81-91, 2011. PMID: 21299461.
Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6):1822-7, 2011. e-Pub 2010. PMID: 21030554.
Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25(2):201-10, 2011. e-Pub 2010. PMID: 20861918.
Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117(2):327-35, 2011. e-Pub 2010. PMID: 20845478.
Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116(24):5568-74, 2010. e-Pub 2010. PMID: 20737576.
Fullmer A, Kantarjian H, Cortes J, Jabbour E. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother 11(18):3065-72, 2010. e-Pub 2010. PMID: 21073351.
Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 2010. e-Pub 2010. PMID: 20668231.
Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. e-Pub 2010. PMID: 21117167.
Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer 116(19):4580-9, 2010. PMID: 20572037.
Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?. Semin Hematol 47(4):344-53, 2010. PMID: 20875551.
Yin CC, Cortes J, Galbincea J, Reddy N, Breeden M, Jabbour E, Luthra R, Jones D. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci 101(9):2005-10, 2010. PMID: 20557306.
Parikh SA, Kadia T, Jabbour E. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. Clin Lymphoma Myeloma Leuk 10(4):301-2, 2010. PMID: 20709669.
Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116(16):3830-4, 2010. PMID: 20564137.
Bryan J, Jabbour E, Prescott H, Kantarjian H. Thrombocytopenia in patients with myelodysplastic syndromes. Semin Hematol 47(3):274-80, 2010. PMID: 20620439.
Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood 115(26):5428-9, 2010. PMID: 20595523.
Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. Drugs 70(11):1381-94, 2010. PMID: 20614946.
Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence - based review. Core Evid 4:207-13, 2010. e-Pub 2010. PMID: 20694077.
Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F. Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency. Clin Lymphoma Myeloma Leuk 10(3):205-10, 2010. PMID: 20511166.
Jabbour E, Fullmer A, Cortés JE, Kantarjian H. Clinical Algorithms for the Treatment of Patients With Chronic Myeloid Leukemia: The 2010 Perspective. Clin Lymphoma Myeloma Leuk 10(Supplement 1):S6-13, 2010. e-Pub 2010. PMID: 20529808.
Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116(10):2290-300, 2010. e-Pub 2010. PMID: 20209620.
Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs 15(1):1-11, 2010. PMID: 20055690.
Fullmer A, Jabbour E. Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?. Am J Hematol 85(3):158-9, 2010. PMID: 20131307.
Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398-404, 2010. e-Pub 2009. PMID: 20008620.
Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-7, 2010. e-Pub 2009. PMID: 20008621.
Fullmer A, Cortes J, Kantarjian H, Jabbour E. ASH 2009 meeting report-Top 10 clinically oriented abstracts in chronic myeloid leukemia. Am J Hematol 85(4):283-286. e-Pub 2010. PMID: 20201083.
Jabbour E. Imatinib: High Dose Versus Standard Dose. Clin Adv Hematol Oncol 7(12):812, 2009. PMID: 20332752.
Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 2009. e-Pub 2009. PMID: 19567878.
Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 27(22):3659-63, 2009. e-Pub 2009. PMID: 19487383.
Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 27(22):3642-9, 2009. e-Pub 2009. PMID: 19506164.
Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-905, 2009. PMID: 19235255.
Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-63, 2009. e-Pub 2009. PMID: 19282457.
Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. Oncologist 14(5):489-96, 2009. e-Pub 2009. PMID: 19365094.
Jabbour E, Soverini S. Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol 46(2 Suppl 3):S22-6, 2009. PMID: 19621546.
Jabbour E, Verstovsek S. Treatment of Myelofibrosis in younger patients: to transplant or not?. Am J Hematol 84(3):131-2, 2009. PMID: 19202548.
Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154-60, 2009. e-Pub 2008. PMID: 19060245.
Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113(9):1892-8, 2009. e-Pub 2008. PMID: 19109226.
Fava C, Kantarjian H, Cortes J, Jabbour E. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther 2:233-43, 2009. e-Pub 2009. PMID: 19920910.
Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4(1):3-10, 2009. e-Pub 2009. PMID: 19343297.
Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-42, 2008. e-Pub 2008. PMID: 18818391.
Jabbour E Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. e-Pub 2008. PMID: None.
Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 113(5):985-94, 2008. e-Pub 2008. PMID: 18615627.
Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 2008. PMID: 18640568.
Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution anaylsis. Biol Blood Marrow Transplant 14(8):859-66, 2008. PMID: None.
Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53-5, 2008. e-Pub 2008. PMID: 18403620.
Jabbour E, El Ahdab S, Cortes J, Kantarjian H. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs 17(7):1127-36, 2008. PMID: 18549348.
Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcome of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 2008. PMID: None.
Jabbour E, J, Cortes JE, Kantarjian H, Quintas-Cardama A, Radich JP, Bixby DL, Talpaz M, Snead JL, O'Hare T, Eide CA, Deininger MW. Optimizing Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A New Era. Clinical Lymphoma & Myeloma Supplement 8(Supplement 3), 2008. PMID: None.
de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2):258-64, 2008. e-Pub 2007. PMID: 17989720.
Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12):4005-11, 2007. e-Pub 2007. PMID: 17785585.
Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a Phase 2 Study. Cancer 110(9):2012-2018, 2007. PMID: 17849460.
Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110(8):2991-2995, 2007. e-Pub 2007. PMID: 17625066.
Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40(5):431-435, 2007. e-Pub 2007. PMID: 17603511.
Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110(6):1295-1302, 2007. PMID: 17623836.
Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110(2):340-4, 2007. PMID: 17559140.
Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 10(7):468-479, 2007. PMID: 17642017.
Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-9, 2007. PMID: 17497648.
Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109(8):3214-8, 2007. e-Pub 2007. PMID: 17209054.
Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol 44(1 Suppl 1):S1-3, 2007. PMID: 17292735.
Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109(2):265-73, 2007. PMID: 17133405.
Jabbour E, Kantarjian H. Integrating the new generation of targeted therapies for chronic myelogenous leukemia - Introduction. Seminars in Hematology 44:S1-S3, 2007. PMID: None.
Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, and Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: Opportunities and challenges. Clinical Lymphoma & Myeloma 7:S51-S57, 2007. PMID: None.
Thomas DA, Jabbour E, Kantarjian H, and O'Brien S. Response: Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen. Blood 110:1698-1699, 2007. PMID: None.
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10):3271-9, 2006. e-Pub 2006. PMID: 16882711.
Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767-1773, 2006. e-Pub 2006. PMID: 16855631.
Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107(7):1525-1529, 2006. PMID: 16955510.
Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 5(9):717-8, 2006. PMID: 17001803.
Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108(4):1421-3, 2006. e-Pub 2006. PMID: 16601247.
Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(1):58-60, 2006. PMID: 16803568.
Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 20(5):814-819, 2006. PMID: 16511514.
Jabbour E, Kantarjian H. Impact of Iron Overload and Transfusion Dependence in Patients With Myelodysplastic Syndromes. Clinical Implications of Anemia 3(1):7-9, 2006. PMID: None.
Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome. Cancer 106(5):1090-1098, 2006. PMID: 16435386.
Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2006. e-Pub 2005. PMID: 16123215.
Kantarjian H, Jabbour E, Grimley J, and Kirkpatrick P. Fresh from the pipeline - Dasatinib. Nature Reviews Drug Discovery 5:717-718, 2006. PMID: None.
Jabbour E, Giles F, Cortes J, O'Brien S, Ravandi F, Borthakur G, Garcia-Manero G, Letvak L, Salvado A, and Kantarjian H. Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Journal of Clinical Oncology 24:358S, 2006. PMID: None.
Quintas-Cardama A, Kantarjian H, Jones D, Talpaz M, Jabbour E, O'Brien S, Luthra R, Wierda W, Nicaise C, and Cortes J. Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. Journal of Clinical Oncology 24:343S, 2006. PMID: None.
Yee KW, Jabbour E, Kantarjian HM, Giles FJ. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol 84:18-24, 2005. PMID: 16273408.
Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11(21):7817-7824, 2005. PMID: 16278404.
Oprea C, Cainap C, Azoulay R, Assaf E, Jabbour E, Koscielny S, Lapusan S, Vanel D, Bosq J, Ribrag V. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol 131(4):468-471, 2005. PMID: 16281936.
Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104(3):541-546, 2005. PMID: 15977212.
Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia - Final results of a phase II study initiated in 1986. Cancer 103(12):2551-2557, 2005. PMID: 15861412.
Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leuk Lymphoma 46(6):861-867, 2005. PMID: 16019530.
Jabbour E, and Ribrag V. Acute tumor lysis syndrome: update on therapy. Revue de Medecine Interne 26:27-32, 2005. PMID: None.
Jabbour E, Kantarjian HM, Garcia-Manero G, Issa JP. Decitabine in myelodysplastic syndromes. Expert Review 2:835-842, 2005. PMID: None.
Jabbour E, Yee K, Giles, F. FLT-3 receptor tyrosine kinase as a drug target in leukemia. Future Oncology 1:323-333, 2005. PMID: None.
Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Faderl S, Verstovsek S, Ravandi F, Rytting M, Cortes J, Wierda W, Hoshino K, Yang H, Santos-Malave C, Fiorentino J, Jabbour E, Rosner G, and Issa JP. Results of a phase I/II study of the combination of 5-aza-2 ' deoxycytidine (DAC) and valproic acid (VPA) in patients (pts) with leukemia. Blood 104:78A-79A, 2004. PMID: None.
Abboud B, Jabbour E, Chahine G. Castelman's disease. Report of two cases with review of the literature. J. Med Liban 49:342-346, 2001. PMID: None.
Tabchi B, Rassi S, Jabbour E, Haddad A, Ne Hme P, el Rassi B. Otosclerosis: experience at the Hotel-Dieu in France. J. Med Liban 48:131-135, 2000. PMID: None.

Invited Articles

Jabbour E. Improving Outcomes of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia. The American Journal of Hematology/Oncology V6 No 12 Supplement 14, 2007. PMID: None.
Jabbour E, Kantarjian HM. Thrombocytopenia and Myelodysplastic Syndrom: Epidemiology, Clinical Consequences, and Management Approaches. An Expert Column for: MEDSCPAE CME SPECIAL REPORT Evolving Concepts in Thrombocytopenia, 2007. PMID: None.

Editorials

Kantarjian HM, Begna K, Jabbour EJ, Paul S, Welch MA, Tefferi A. Optimal frontline therapy of chronic myeloid leukemia today, and related musings. Am J Hematol 99(10):1855-1861, 2024. PMID: 39092929.
Short NJ, Kantarjian H, Jabbour E. Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?. Expert review of hematology 17(6):189-191, 2024. PMID: 38726703.
Jabbour E, Kantarjian H. A new era in the treatment of acute lymphoblastic leukemia. Blood 137(12):1563-1564, 2021. PMID: 33764428.
Jabbour E, Kantarjian H. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 21(1):63-65, 2021. PMID: 33191168.
Kadia T, Jabbour E, O'Brien S. Treatment strategies for chronic lymphocytic leukemia. US Oncological Disease, 2006. PMID: None.

Abstracts

Kadia TM, Boddu PC, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour E, Dinardo CD, Konopleva M, Daver NG, Takahashi K, Patel K, Kanagal-Shamanna R, Cortes JE, Kantarjian HM. Outcomes with lower intensity therapy in TP53-mutated AML. Journal of Clinical Oncology 35(15):7017, 2017. PMID: None.
Masarova L, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG. Phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. Journal of Clinical Oncology 35(15):7063, 2017. PMID: None.
Benton CB, Diaz-Pavon JR, Maiti A, Daver NG, Ravanvdi F, Jain N, Alvalrado Y, Jabbour E, Pierce S, Kwari M, Santos MA, Martinez S, Siguero M, Tefferi A, Cortes JE, Kantarjian HM Pardanani AD, Garcia-Manero G. Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS. Journal of Clinical Oncology 35(15):e18521, 2017. PMID: None.
Ohanian M, Garcia-Manero G, Levis MJ, Jabbour E, Daver NG, Borthakur G, Kadia TM, Brandt M, Pierce S, Burger JA, Richie MA, Patel K, Cortes JE, Kantarjian HM, Ravandi F. Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML. Journal of Clinical Oncology 35(15):7029, 2017. PMID: None.
Short JN, Kantarjian HM, O'Brien SM, Ravandi F, Thomas DA, Garcia-Manero G, Daver NG, Borthakur G, Jain N, Konopleva M, Sasaki K, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson PA, Cortes JE, Jabbour E. Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. Journal of Clinical Oncology 35(15):7014, 2017. PMID: None.
Assi R, Kantarjian HM, O'Brien SM, Kebriaei P, Thomas DA, Garcia-Manero G, Khouri IF, Champlin RE, Kadia TM, Cortes JE, Jain N, Konopleva M, Khouri R, Estrov Z, Takahashi K, Sasaki K, Jacob J, Garris R, Jabbour E. Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 35(15):7025, 2017. PMID: None.
Pierola AA, Montalban-Bravo G, Takahashi K, Jabbour E, Kadia TM, Ravandi F, Cortes JE, Dinardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramo CE, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of the type of first-cancer therapy in therapy-related myelodysplastic syndromes outcomes. Journal of Clinical Oncology 35(15):e18555, 2017. PMID: None.
Boddu, P, Jorgensen JL, Kantarjian HM, Borthakur G, Kadia TM, Daver NG, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, Dinardo CD, Jabbour E, Garcia-Manero G, Cortes JE, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse. Journal of Clinical Oncology 35(15):7018, 2017. PMID: None.
Naqvi K, Norgueras-Gonzalez, Cheung CM, Pemmaraju N, Jabbour E, Garcia-Manero G, Dinardo CD, Ohanian M, Jain N, Takahashi K, Alvarado Y, Konopleva M, Huang X, Cortes JE, Kantarjian HM. A Bayesian randomized phase II study of guadecitabine (SGI-110) based regimens comparing guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + idarubicin (SGI5 + Ida), 5 days + cladribine (SGI5 + Clad), in untreated patients ≥ 70 years with acute myeloid leukemia (AML). Journal of Clinical Oncology 35(15):7019, 2017. PMID: None.
ChamounK, Gulbis A, Milton D, Jabbour E, Turturro F, Khouri IF. Bortezomib, rituximab, and risk of graft-versus-host disease (GVHD) after BEAM conditioning for allogeneic stem cell transplantation (alloSCT). Journal of Clinical Oncology 35(15):e18543, 2017. PMID: None.
Montalban-Bravo G, Pierola AA, Takahashi K, Konopleva M, Jabbour E, Borthakur G, Daver NG, Dinardo CD, Estrov Z, Kadia TM, Pemmaraju N, Ravandi F, Bueso-Ramos CE, Kantarjian HM, Patel K, Garcia-Manero G. Clinical relevance of mutations in patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms with normal karyotype. Journal of Clinical Oncology 35(15):7053, 2017. PMID: None.
Cortes JE, Hochhaus A, Kantarjian HM, Guilhot F, Kota VK, Hughes TP, s S, Li L, Jabbour E. Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION. Journal of Clinical Oncology 35(15):7051, 2017. PMID: None.
Issa GC, Kantarjian HM, Short NJ, Ravandi F, Huang X, Garcia-Manero G, Plunkett W, Gandhi V, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Dinardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study. Journal of Clinical Oncology 35(15):7037, 2017. PMID: None.
Morita K, Wang F, Patel K, Bueso-Ramos CE, Zahr AA, Gumbs C, Zhang J, Song X, Mendoza M, Wu C, Kornblau S, Dinardo CD, Ravandi F, Garcia-Manero G, Jabbour E, Andreeff M, Kantarjian HM, Konopleva M, Futreal A, Takahashi K. Genomic landscape of adult mixed phenotype acute leukemia (MPAL). Journal of Clinical Oncology 35(15):7023, 2017. PMID: None.
Short JN, Kantarjian HM, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, Yilmaz M, Kadia TM, Sasaki K, Garris R, Garcia-Manero G, Dinardo CD, Konopleva M, Estrov Z, Jain N, Wierda WG, Jeanis V, Cortes JE, O'Brien SM, Jabbour E. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. Journal of Clinical Oncology 35(15):7013, 2017. PMID: None.
Naqvi K, Cortes JE, Skinner JA, Jabbour E, Pemmaraju N, Borthakur G, Estrov Z, Bose P, Thompson PA, Kantarjian HM. Early results of lower-dose dasatinib, 50 mg daily, in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Journal of Clinical Oncology 35(15):e18551, 2017. PMID: None.
Takahashi K, Wang F, Keyur P, Bueso-Ramos CE, Issa GC, Song X, Zhang J, Tippen S, Little L, Gumbs C, Ravandi F, Kadia TM, Daver NG, Dinardo CD, Konopleva M, Andreeff M, Cortes JE, Jabbour E, Futreal A, Kantarjian HM. Distinct patterns of somatic mutation clearance and association with clinical outcome in patients with AML. Journal of Clinical Oncology 35(15):7005, 2017. PMID: None.
Pierola AA, Montalban-Bravo G, Takahashi K, Jabbour E, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Pierce S, Kantarjian HM, Garcia-Manero AG. Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia. Blood 128(22):111, 2016. PMID: None.
Bose P, Daver N, Jabbour E, Pike A, Newberry KJ, Zhou L, Pierce S, Wang X, Kantarjian HM, Verstovsek AS. Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood 128(22), 2016. PMID: None.
Bose P, Daver N, Jabbour E, Pike A, Newberry KJ, Zhou L, Pierce S, Wang X, Kantarjian HM, Verstovsek AS. Cryptic Philadelphia Chromosome in Newly Diagnosed Chronic Phase CML (CML-CP): Clinical Characteristics and Treatment Outcome after Treatment with 5 TKI Modalities. Blood 128(22):3082, 2016. PMID: None.
Kantarjian HM, Su Y, Helen Bhattacharyya JE, Yan E, Shapiro M, Cappelleri JC, I Marks AD. Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood 128(22):1599, 2016. PMID: None.
Khouri IF, Erwin B, Gulbis AM, Turturro F, Kappadath S, Gress D, Valverde RB, Jabbour E, Bassett Jr RL, Jessop AA. Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan (90YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies. Blood 128(22):662, 2016. PMID: None.
Zahr AA, Cortes JE, Verstovsek S, Matthews J, Jain N, Jabbour E, Garcia-Manero G, Andreef M, Naqvi K, Kantarjian HM, Borthakur AG. Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis. Blood 128(44):3062, 2016. PMID: None.
Advani AS, Jabbour E, Stelljes M, DeAngelo DJ, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella M, Sleight B, Vandendries E, M Kantarjian AH. Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase. Blood 128(22):5188, 2016. PMID: None.
Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, M Kantarjian AH. A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia. Blood 128(22):5189, 2016. PMID: None.
Abaza Y, Kantarjian HM, Borthakur G, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger JA, Estrov Z, Ohanian M, Lim M, Assi R, Jabbour E, E Cortes AJ. An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). Blood 128(22):5433, 2016. PMID: None.
Maiti A, Kantarjian HM, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien SM, E Cortes AJ. Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML). Blood 128(22):5449, 2016. PMID: None.
Daver N, Cortes JE, Pemmaraju N, Jabbour EJ, Bose P, Zhou L, Pierce S, Derbur SV, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek AS. Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF). Blood 128(22):1127, 2016. PMID: None.
Jabbour E, Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva AD. Evaluation of Healthcare Resource Utilization and Costs Among Patients with Chronic Myeloid Leukemia after Disease Progression. Blood 128(22):3573, 2016. PMID: None.
Thompson PA, Strati P, Keating M, O'Brien SM, Ferrajoli A, Burger JA, Jorgensen JL, Faderl S, Estrov Z, Jain N, Kadia T, Borthakur G, DiNardo CD, Daver NG, Jabbour E, G Wierda AW. Early Achievement of MRD-Negativity in IGHV-Mutated (IGHV-M) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse. Blood 128(22):232, 2016. PMID: None.
Han L, Zhang Q, Shi C, Cavazos A, Ruvolo V, Leverson J, Monique D, Phillips DC, Chen J, Jin SS, Jacamo RO, Daver N, Jabbour E, Kantarjian HM, Andreeff M, Sampath D, Konopleva AM. Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models. Blood 128(22):97, 2016. PMID: None.
Sasaki K, Jabbour E, O'Brien SM, Ravandi F, Thomas DA, Garcia-Manero G, Daver N, Borthakur G, Jain N, Konopleva M, Short NJ, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson PA, Cortes JE, M Kantarjian AH. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128(22):588, 2016. PMID: None.
Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, E Cortes AJ. Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 128(22):1224, 2016. PMID: None.
Sasaki K, Kantarjian HM, Jabbour E, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Jain P, Skinner J, Rios MB, Pierce S, Garcia-Manero G, E Cortes AJ. Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood 128(22):940, 2016. PMID: None.
Khouri IF, Curbelo IF, Turturro F, Milton DR, Kim RA, Jabbour E, Bassett Jr RL, Vence LM, Sharma P, M Gulbis AA. Lenalidomide with Ipilimumab for Lymphoid Malignancies after Allogeneic or Autologous Stem Cell Transplantation (SCT). Blood 128(22):1164, 2016. PMID: None.
Ohanian M, Garcia-Manero G, Jabbour E, Daver N, Borthakur G, Kadia TM, Brandt M, Pierce S, Burger J, Richie MA, Patel K, Cortes JE, Kantarjian HM, Ravandi AF. Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation. Blood 128(22):1611, 2016. PMID: None.
Short NJ, Ravandi F, Cortes JE, Garris R, O'Brien SM, Patel KP, Jorgensen JL, Khoury JD, Garcia-Manero G, Thomas DA, Kantarjian HM, and Jabbour E. Patterns of Relapse in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Achieve Complete Molecular Response with Chemotherapy Plus a Tyrosine Kinase Inhibitor. Blood 128(22):3977, 2016. PMID: None.
Kantarjian HM, Jabbour E, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Zhang C, Ravandi F, Plunkett AW. Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study. Blood 128(22):2822, 2016. PMID: None.
Boddu PC, Kantarjian HM, Garcia-Manero G, Verstovsek S, Ravandi F, Jabbour E, Takahashi K, Bhalla KN, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, M Kadia AT. Characteristics and Outcomes of Older Patients with Secondary AML According to Treatment Approach. Blood 128(22):2788, 2016. PMID: None.
Chamoun K, Kantarjian HM, Rios MB, Assi R, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia TM, Pemmaraju N, Jabbour E, E Cortes AJ. CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. Blood 128(22):1923, 2016. PMID: None.
Abaza Y, Jabbour E, Verstovsek S, Estrov Z, Ravandi F, Borthakur G, Kadia TM, Daver N, DiNardo CD, Bueso-Ramos CE, Hidalgo JE, Schneider H, Bravo GM, Alfonso A, Wei Y, Kantarjian HM, Garcia-Manero AG. Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. Blood 128(22):4318, 2016. PMID: None.
Kanagal-Shamanna R, Hidalgo Lopez JE, Kim HR, Zuo Z, Martinez MJ, Zhao C, Milton DR, Stingo F, Lee J, Luthra R, Patel KP, Jabbour E, Garcia-Manero G, Medeiros L, E Bueso-Ramos AC. Validation of the 2016 Revision to the World Health Organization (WHO) Classification of Myelodysplastic Syndromes with Diploid Karyotype. Blood 128(22):4319, 2016. PMID: None.
Jabbour E. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood 128(22):4328, 2016. PMID: None.
Patel YB, Voit KN, Sasaki K, Ravandi F, Thomas DA, O'Brien SM, Borthakur G, Garcia-Manero G, Cortes JE, Konopleva M, Jain N, Ohanian M, Garris R, Jacob J, Kantarjian HM, and Jabbour E. Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. Blood 128(22):5194, 2016. PMID: None.
Montalban-Bravo G, Pierola AA, Takahashi K, Jabbour E, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Pierce S, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero AG. Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood 128(22):3171, 2016. PMID: None.
Montalban-Bravo G, Pierola AA, Takahashi K, Jabbour E, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Pierce S, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero AG. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood 128(22):3171, 2016. PMID: None.
Baran N, Molina J, Cavazos A, Harutyunyan K, Feng N, Gay J, Piya S, Velandy SS, Jabbour E, Andreeff M, Tiziani S, Ferrando AA, Zweidler-McKay P, Francesco M, Marszalek JR, Konopleva AM. Mitochondrial Complex I Inhibition with Iacs-010759 in T-ALL Preclinical Models. Blood 128(22):4028, 2016. PMID: None.
Assi R, Kantarjian HM, Verstovsek S, Garcia-Manero G, Konopleva M, Ravandi F, DiNardo CD, Kadia TM, Daver N, Jabbour E, Gborogen RA, Chamoun K, Wierda WG, Borthakur G, E Cortes AJ. CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. Blood 128(22):4047, 2016. PMID: None.
Jain N, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, Jabbour E, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Alvarado Y, Takahashi K, Benton CB, Pike A, Pierce S, Cortes JE, M Kantarjian AH. Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood 128(22):2817, 2016. PMID: None.
Garcia-Manero G, Yang H, Fang Z, Kantarjian HM, DiNardo CD, Jabbour E, Pemmaraju N, Daver N, Delumpa R, Loiselle C, Rivera S, Anderson K, Yearby B, Denton S, Smith W, Tiefenwerth K, Iwamura H, Gipson T, Rosner M, Myers TJ, J Paradiso AL. Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. Blood 128(22):1640, 2016. PMID: None.
Abdelall W, Kantarjian HM, Borthakur G, Garcia-Manero G, Patel KP, Jabbour E, Daver NG, Kadia T, Gborogen RA, Konopleva M, Ravandi F, Andreef M, E Cortes AJ. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 128(22):1642, 2016. PMID: None.
Abaza Y, Kantarjian HM, Jabbour E, Thomas DA, Kadia TM, Borthakur G, Burger J, Wierda WG, Jain N, Faderl S, O'Brien SM, Konopleva M, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Kelly MA, Garris R, Garcia-Manero G, Cortes JE, Ravandi AF. Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood 128(22):177, 2016. PMID: None.
Lane AA, Sweet KL, Wang ES, Donnellan WB, Walter RB, Stein AS, Rizzieri DA, Carraway HE, Mantzaris I, Prebet T, Maris MB, Faderl S, Bixby DL, Chen J, Lindsay R, Shemesh S, Brooks CL, Stone RM, Kantarjian HM, Jabbour E, Konopleva AM. Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). Blood 128(22):215, 2016. PMID: None.
Jabbour E, Short NJ, Huang X, Maiti A, Kadia TM, Daver N, Borthakur G, DiNardo CD, Pemmaraju N, Sasaki K, Estrov Z, Verstovsek S, Ravandi F, Alvarado Y, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Miller D, Dong X, Kantarjian HM, Garcia-Manero AG. A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood 128(22):226, 2016. PMID: None.
Garcia-Manero G, Daver NG, Montalban-Bravo G, Jabbour E, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, M Kantarjian AH. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood 128(22):344, 2016. PMID: None.
Benton CB, Takahashi K, Bose P, Wang F, Chen H, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa GC, Daver N, Jabbour E, DiNardo CD, Bueso-Ramos CE, Patel K, Kornblau SM, Konopleva M, Borthakur G, Kadia TM, Cortes JE, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, M Kantarjian AH. Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. Blood 128(22):597, 2016. PMID: None.
Sasaki K, Jabbour E, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, Khouri RB, Yilmaz M, Kadia TM, Short NJ, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda WG, Jeanis TV, Cortes JE, O'Brien SM, M Kantarjian AH. Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Blood 128(22):757, 2016. PMID: None.
Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Pemmaraju N, Bueso-Ramos CE, Blando J, Hidalgo Lopez JE, Allison J, Kantarjian HM, Sharma AP. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood 128(22):763, 2016. PMID: None.
Short NJ, Ravandi F, Huang X, Cortes JE, Pemmaraju N, Daver N, Khouri RB, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, Kadia TM, Wierda WG, DiNardo CD, O'Brien SM, Shah S, Pike A, Brandt M, Kantarjian HM, and Jabbour E. Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood 128(22):1067, 2016. PMID: None.
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig M, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst H, Recher C, Klimek VM, Cortes JE, Roboz GJ, Craig AR, Ward R, Smith J, Kantarjian HM, K Stuart AR. Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial. Blood 128(22):903, 2016. PMID: None.
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig M, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst H, Recher C, Klimek VM, Cortes JE, Roboz GJ, Craig AR, Ward R, Smith J, Kantarjian HM, K Stuart AR. Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies. Blood 128(22):904, 2016. PMID: None.
Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour E, Cortes JE, Ravandi AF. Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood 128(22):1612, 2016. PMID: None.
Short NJ, Kantarjian HM, Jorgensen JL, Ravandi F, Yilmaz M, Khouri MR, Wang S, Thomas DA, Khoury JD, Champlin RE, Khouri IF, Kebriaei P, Marin D, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, DiNardo CD, Kadia TM, Jain N, Konopleva M, Garris R, and Jabbour E. Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. Blood 128(22):2916, 2016. PMID: None.
Kanagal-Shamanna R, Jain P, Luthra R, Patel KP, Garcia-Manero G, Takahashi K, Ravandi F, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Estrov Z, Wierda WG, O'Brien SM, Cortes JE, Kantarjian HM, and Jabbour E. Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. Blood 128(22):2917, 2016. PMID: None.
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia TM, Cortes JE, Daver N, Takahashi K, DiNardo CD, Jabbour E, Borthakur G, Konopleva M, Pierce S, Patel KP, Kornblau SM, Kantarjian HM, Young KH, Garcia-Manero G, Andreeff AM. Pure Erythroid Leukemia Is Characterized By TP53mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. Blood 128(22):2852, 2016. PMID: None.
Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes JE, Verstovsek S, Kadia TM, Daver NG, Wierda WG, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Pierola AA, Brandt M, Sneed T, Chen H, Yang H, Bueso-Ramos CE, Pierce S, Estey EH, Bohannan ZS, Kantarjian HM, Garcia-Manero AG. A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials. Blood 128(22):1999, 2016. PMID: None.
Jain N, Roberts KG, Jabbour E, Patel K, Eterovic K, Fawcett G, Zweidler-McKay P, Lu X, Wang S, Konoplev S, Harvey RC, Chen IL, Payne-Turner D, Valentine M, Thomas DA, Garcia-Manero G, Ravandi F, Cortes JE, Kornblau SM, O'Brien SM, Pierce S, Jorgensen JL, Shaw K, Willman CL, Mullighan C, Kantarjian HM, Konopleva AM. High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy. Blood 128(22):1082, 2016. PMID: None.
Jabbour E, Kantarjian HM, Sasaki K, Kadia TM, Ravandi F, Cortes JE, Khoury JD, Patel KP, Bueso-Ramos CE, Daver NG, Borthakur G, Jain N, DiNardo CD, Konopleva M, Verstovsek S, Pemmaraju N, Estrov Z, Miller D, Maduike R, Faderl S, Garcia-Manero AG. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. Blood 128(22):3166, 2016. PMID: None.
Pierola AA, Montalban-Bravo G, Takahashi K, Wang F, Xingzhi S, Jabbour E, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero AG. STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes. Blood 128(22):3177, 2016. PMID: None.
Jain P, Kantarjian HM, Ravandi F, Kanagal-Shamanna R, Khoury JD, Patel KP, Garcia-Manero G, Konopleva M, Jain N, Sasaki K, Kadia TM, Borthakur G, Garris R, Pierce S, Estrov Z, Wierda WG, Cortes JE, O'Brien SM, and Jabbour E. Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. Blood 128(22):2779, 2016. PMID: None.
Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour E, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Borthakur G, Pemmaraju N, Bueso-Ramos CE, Hidalgo Lopez JE, Blando J, Allison J, Kantarjian HM, Sharma AP. Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood 128(22):1641, 2016. PMID: None.
Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour E, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Brandt M, Pierce S, Nogueras-Gonzalez GM, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi AF. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood 128(22):4262, 2016. PMID: None.
Ohanian M, Kantarjian HM, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour E, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt JR, Ravandi F, E Cortes AJ. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood 128(22):2744, 2016. PMID: None.
Sasaki K, Kantarjian HM, Ravandi F, Daver N, Kadia TM, Khouri RB, Alvarado Y, Burger JA, Thomas DA, Garcia-Manero G, DiNardo CD, Pemmaraju N, Short NJ, Schroeder H, Garris R, Bose P, Jain N, Naqvi K, Wierda WG, Verstovsek S, Cortes JE, Konopleva M, O'Brien SM, and Jabbour E. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128(22):2783, 2016. PMID: None.
Jain P, Casteel K, Allen CE, McClain KL, Wang S, Konoplev S, Jabbour E, Gonzalez GN, Huang X, Miller S, Abdelall W, Tamamyan G, Kadia TM, Borthakur G, Estrov Z, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM, Daver AN. Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation. Blood 128(22):2791, 2016. PMID: None.
Pierola AA, Montalban-Bravo G, Chamseddine AN, Takahashi K, Wang F, Xingzhi S, Jabbour E, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero AG. Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome. Blood 128(22):4340, 2016. PMID: None.
Pierola AA, Montalban-Bravo G, Takahashi K, Wang F, Xingzhi S, Jabbour E, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero AG. Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome. Blood 128(22):3177, 2016. PMID: None.
Aoki E, Jain P, Ferrajoli A, Estrov Z, Keating M, O'Brien SM, Wierda WG, Jain N, Thompson PA, Jabbour E, Pierce S, Hosing C, Kantarjian HM, Ravandi F, M Kadia AT. Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience. Blood 128(22):2997, 2016. PMID: None.
Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson A, Alousi A, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei AP. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Blood 128(22):4680, 2016. PMID: None.
Sam PY, Ahaneku H, Nogueras-Gonzalez GM, Jabbour E, Garcia-Manero G, Borthakur G, Wierda WG, Daver N, Kadia T, Burger J, Pierce S, DiNardo CD, Ravandi F, Kantarjian HM, E Cortes AJ. Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood 128(22):1919, 2016. PMID: None.
Jain P, Kantarjian HM, Ravandi F, Jabbour E, Daver N, Pemmaraju N, DiNardo CD, Alvarado Y, Jain N, Borthakur G, Verstovsek S, Ferrajoli A, Ohanian M, Konopleva M, Naqvi K, Fitch T, Garcia-Manero G, Cortes JE, Estrov Z, M Kadia AT. Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood 128(22):1639, 2016. PMID: None.
Sasaki K, Jabbour E, O'Brien SM, Thomas DA, Ravandi F, Garcia-Manero G, Cortes JE, Short NJ, Verstovsek S, Yilmaz M, Wierda WG, Borthakur G, Kadia TM, Konopleva M, Khouri MR, Ferrajoli A, Daver NG, Pemmaraju N, DiNardo CD, Jain N, Benton CB, Takahashi K, Naqvi K, Bose P, Kornblau SM, Andreeff M, Keating MJ, Freireich EJ, M Kantarjian AH. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood 128(22):3975, 2016. PMID: None.
Shrestha R, Al-Attar A, Hayslip JW, Charles LT, Dressler E, Hossam J, Zia MF, Saeed H, Goldberg A, Monohan G, Herzig R, Fleischman RA, Jabbour E, Hildebrandt G, A Shakil AS. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 128(22):346, 2016. PMID: None.
Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei AP. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood 128(22):4676, 2016. PMID: None.
Cortes JE, Kantarjian HM, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Daver NG, Pemmaraju N, Jabbour E, a R, Paradel J, Pond B, Ravandi F, Vusirikala M, Patel PA, Levis M, Perl AE, Andreeff M, Collins R. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. Journal of Clinical Oncology 34(15):7008, 2016. PMID: None.
Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gokbudget N, Martinelli G, O'Brien SM, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, DeAngelo D, Kantarjian HM. Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial. Journal of Clinical Oncology 34(15):7029, 2016. PMID: None.
Short NJ, Jabbour E, Cortes JE, Garris R, O'Brien SM, Patel K, Sasaki K, Issa GC, Garcia-Manero G, Thomas DA, Kantarjian HM, Ravandi F. Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 34(15):7034, 2016. PMID: None.
DeAngelo DJ, Jabbour E, Stelljes M, Liedtke M, Stock W, Gokbudet N, Martinelli G, O'Brien SM, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM. Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy. Journal of Clinical Oncology 34(15):7028, 2016. PMID: None.
Maiti A, Kantarjian HM, Patel K, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Kadia TM, Skinner JA, Poku RA, Dellasala S, Luthra R, Jabbour E, Cortes JE. Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP). Journal of Clinical Oncology 34(15):e18542, 2016. PMID: None.
Khouri IF, Wang X, Turturro F, Jabbour E, Carballo-Zarate AA, Korbline M, Alousi AM, Oran B, Anderlini P, Ciurea SO, Patel KK, Marin D, Nastoupil LJ, Fanale MA, Samuels BI, Gulbis AM, Medeiros LJ, Khoury J. Long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL). Journal of Clinical Oncology 34(15):7551, 2016. PMID: None.
Ohanian M, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Alvarado Y, Konopleva M, Lim M, Pierce S, O'Brien SM, Ashizawa AT, Verstovsek S, Wierda WG, Cortes JE. Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies. Journal of Clinical Oncology 34(15):7010, 2016. PMID: None.
Issa GC, Kantarjian HM, Yin CC, Ravandi F, Garcia-Manero G, Thomas DA, Cortes JE, Short NJ, Sasaki K, Qiao W, Takahashi K, Pierce S, Verstovsek S, Kadia TM, Borthakur G, O'Brien SM, Jabbour E. Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 34(15):7038, 2016. PMID: None.
Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Garcia-Manero G, Thomas DA, Pierce S, Issa GC, Cortes JE, Kadia TM: Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 34(15):7035, 2016. PMID: None.
Sasaki K, Kantarjian HM, Ravandi F, Thomas DA, Daver NG, Kadia TM, Konopleva M, Jain N, Short NJ, Issa GC, Jeanis V, Moore HG, Garris RS, Garcia-Manero G, Cortes JE, O'Brien SM, Jabbour E. Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Journal Of Clinical Oncology 34(15):7025, 2016. PMID: None.
Hu B, Kantarjian HM, Ravandi F, Borthakur G, Kadia TM, Ferrajoli A, Wierda WG, Garcia-Manero G, Daver NG, Pemmaraju N, Dellasala S, Pierce S, Jabbour E, Cortes JE. Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI). Journal of Clinical Oncology 34(15):7057, 2016. PMID: None.
Sasaki K, Kantarjian HM, Ravandi F, Thomas DA, Cortes JE, Pemmaraju N, Kadia TM, Short NJ, Issa GC, Garris RS, Jeanis V, Moore HG, Garcia-Manero G, Borthakur G, Wierda WG, Gachimova E, O'Brien SM, Jabbour E. Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 34(15):7036, 2016. PMID: None.
Issa GC, Kantarjian HM, Yin C, Sasaki K, Garcia-Manero G, DiNardo C, Takahashi K, Ravandi F, Cortes JE, Daver N, Kadia T, Verstovsek S, Pierce S, Jabbour E. Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD. Blood, 2015. PMID: None.
Sasaki K, Jabbour E, Thomas DA, Khouri MR, Yilmaz M, Garcia-Manero G, Ravandi F, Borthakur G, Garris R, Gachimova E, Chahoud J, DiNardo C, Pemmaraju N, Cortes JE, Kantarjian HM, O'Brien S. Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. Blood, 2015. PMID: None.
Khouri IF, Jabbour E, Saliba RM, Ledesma C, Burger JA, O'Brien S, Gulbis AM. Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT). Blood, 2015. PMID: None.
Sasaki K, Koller PB, Kantarjian HM, Thomas DA, Khouri MR, Garcia-Manero G, Garris R, Cortes JE, Schroeder H, Chahoud J, Kadia T, Ravandi F, Verstovsek S, Daver N, Jain N, Konopleva M, O'Brien S, Jabbour E. Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2015. PMID: None.
Sasaki K, Kantarjian HM, O'Brien S, Thomas DA, Ravandi F, Garcia-Manero G, Kadia T, Jain N, Konopleva M, Estrov Z, Takahashi K, Khouri MR, Jacob J, Garris R, Cortes JE, Jabbour E. Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2015. PMID: None.
Patel YB, Kantarjian HM, Thomas D, O'Brien S, Ravandi F, Garcia-Manero G, Cortes JE, Konopleva M, Jain N, Garris R, Autry J, Jabbour E. Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab. Blood, 2015. PMID: None.
Chahoud J, Kantarjian HM, Garcia-Manero G, Sasaki K, Kadia T, Cortes JE, Khouri MR, Ravandi F, Dahl J, Ferrajoli A, Jacob J, Pemmaraju N, Daver N, Garris R, Jabbour E. Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. Blood, 2015. PMID: None.
Kantarjian H, Jabbour E, Garcia-Manero G, Kadia T, DiNardo C, Daver N, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Plunkett W. Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia. Blood, 2015. PMID: None.
Sasaki K, O'Brien S, Ravandi F, Thomas DA, Moore HG, Cortes JE, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jeanis TV, Chahoud J, Borthakur G, Wierda W, Ferrajoli A, Kantarjian HM, Jabbour E. Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. Blood, 2015. PMID: None.
Short NJ, Garcia-Manero G, Bravo GM, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian HM, Jabbour E. Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2015. PMID: None.
Short NJ, Garcia-Manero G, Bravo GM, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian HM, Jabbour E. Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2015. PMID: None.
Jain P, Kantarjian HM, Jabbour E, Estrov Z, Borthakur G, Pemmaraju N, Kadia T, Daver N, Ravandi F, Verstovsek S, O'Brien S, Cortes JE. Outcomes of Patients with Chronic Phase CML Who Discontinued Ponatinib in the Frontline Setting. Blood, 2015. PMID: None.
Ravandi F, Jeffrey JL, Jabbour E, Borthakur G, Kadia T, Faderl S, Pierce S, Brandt M, Wang SA, Konoplev S, Daver N, Pemmaraju N, Garcia-Manero G, Andreeff M, Konopleva M, Cortes JE, Kantarjian HM. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia. Blood, 2015. PMID: None.
Dahl J, Kantarjian HM, Yilmaz M, Kadia T, Garcia-Manero G, Ravandi F, Borthakur G, Cortes JE, Ferrajoli A, Sasaki K, Chahoud J, Autry J, Garris R, Jabbour E. Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure. Blood, 2015. PMID: None.
Yilmaz M, Kantarjian HM, Ravandi F, Jorgensen JL, Wang S, Garcia-Manero G, Cortes JE, Sasaki K, DiNardo C, Kadia T, Autry J, Garris R, Jabbour E. The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2015. PMID: None.
Issa GC, Kantarjian HM, Jabbour E, Borthakur G, Verstovsek S, Pierce S, Wierda W, Ferrajoli A, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Ravandi F, DellaSala SE, Cortes JE. Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Blood, 2015. PMID: None.
Jabbour E, O'Brien S, Sasaki K, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, Jain N, Konopleva M, Jacob J, Garris R, Cortes JE, Kantarjian HM. Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2015. PMID: None.
Kadia T, Cortes JE, Jabbour E, Daver N, Pemmaraju N, Ravandi F, Jain N, Verstovsek S, DiNardo C, Alvarado Y, Ferrajoli A, Burger JA, Garcia-Manero G, Ohanian M, Konopleva M, Estrov Z, Wierda W, Brandt M, Fitch T, Borthakur G, Kantarjian HM. Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood, 2015. PMID: None.
Montalban-Bravo G, Garcia-Manero G, Short NJ, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Konopleva M, Cortes JE, Kantarjian HM, Jabbour E. Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). Blood, 2015. PMID: None.
Montalban-Bravo G, Kantarjian HM, Cortes JE, Ravandi F, Garcia-Manero G, Punit J, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Pierce S, O'Brien S, Jabbour E. Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL). Blood, 2015. PMID: None.
Chahoud J, Kantarjian HM, Ravandi F, Sasaki K, Garcia-Manero G, Cortes JE, Kadia T, Brandt M, Jabbour E. The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience. Blood, 2015. PMID: None.
Parseghian C, Kantarjian HM, Cortes JE, Garcia-Manero G, Konopleva M, Wierda W, Kadia T, Verstovsek S, Sasaki K, Ravandi F, Takahashi K, Jain N, Pierce S, Jabbour E. Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure. Blood, 2015. PMID: None.
Montalban-Bravo G, Kantarjian HM, Jain PL, Garcia-Manero G, Ravandi F, Cortes JE, Daver N, Takahashi K, Jain N, Verstovsek S, Kadia T, Pierce S, Jabbour E. Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse. Blood, 2015. PMID: None.
Yilmaz M, Kantarjian HM, Cortes J, Garcia-Manero G, Chahoud J, Ravandi F, Sasaki K, Konopleva M, Takahashi K, Wierda WG, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Jabbour E. Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood, 2015. PMID: None.
Jain PL, Sasaki K, Kantarjian H, Ravandi F, Cortes JE, Garcia-Manero G, Bose P, Daver N, Kadia T, Verstovsek S, Konopleva M, Jain N, Montalban GB, Pierce S, Jabbour E. Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood, 2015. PMID: None.
Sallman D, Garcia-Manero G, Jabbour E, Sekeres MA, DeZern AE, Steensma DP, Roboz GJ, Barnard J, Al Ali NH, Zimmerman C, Pierce S, Batista D, Lancet JE, Padron E, Maciejewski JP, List AF, Kantarjian HM, Komrokji RS. Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities. Blood, 2015. PMID: None.
Koller PB, Sasaki K, Ravandi F, Garcia-Manero G, O'Brien S, Cortes JE, Kadia T, Borthakur G, Pemmaraju N, Daver N, Chahoud J, Pike A, Brandt M, Pierce S, Kantarjian HM, Jabbour E. Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. Blood, 2015. PMID: None.
Short NJ, Kantarjian HM, Jabbour E, O'Brien S, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia T, Daver N, Borthakur G, Cortes JE, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission Is Not Prognostic for Relapse-Free or Overall Survival in Adult Patients with Acute Lymphoblastic Leukemia. Blood, 2015. PMID: None.
Jabbour E, Kantarjian, H, Thomas, D, Sasaki, K, Garcia-Manero, G, Garris, R, Cortes, J, Kadia, T, Ravandi, F, Verstovsek, S, O’Brien, S. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab as Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2014. PMID: None.
Jabbour E, O’Brien, S, Thomas, D, Sasaki, K, Garcia-Manero, G, Kadia, T, Jain, N, York, S, Garris, R, Cortes, J, Kantarjian, H. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2014. PMID: None.
Jabbour E, Makenbaeva, D, Lingohr-Smith, M, Lin, Jay. Potential Economic Consequences of Genetic Mutations and Restricted Access to Tyrosine Kinase Inhibitor Treatments Among Patients with Chronic Myelogenous Leukemia in the USA. Blood, 2014. PMID: None.
Jabbour E, Makenbaeva, D, Lingohr-Smith, M, Lin, J. Evaluation of Comorbidities Relevant to Tyrosine Kinase Inhibitor Treatment Among Patients with Chronic Myelogenous Leukemia in the U.S. Managed Care Setting. Blood, 2014. PMID: None.
Jabbour E, O’Brien, S, Thomas, D, Sasaki, K, Garcia-Manero, G, Ravandi, F, Borthakur, G, York, S, Garris, R, Cortes, J, Kantarjian, H. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (≥60 years) with Acute Lymphoblastic Leukemia (ALL). Blood, 2014. PMID: None.
Jabbour E, Sasaki, K, Daver, N, Pemmaraju, N, Jain, N, Kadia, T, DiNardo, C, Tuttle, C, Borthakur, G, Konopleva, M, Faderl, S, O’Brien, S, Cortes, J, Kantarjian, H, Garcia-Manero, G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood, 2014. PMID: None.
Jabbour E, Sasaki, K, Daver, N, Pemmaraju, N, DiNardo, C, Kadia, T, Miller, D, Sukholutsky, V, Huang, X, Borthakur, G, Estrov, Z, Kantarjian, Garcia-Manero H, G. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood, 2014. PMID: None.
Jabbour E, O'Brien, S, Sasaki, K, Huang, X, Thomas, D, Rytting, M, Garcia-Manero, G, Cortes, J, Pierce, S, Kadia, T, Kantarjian, H. Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. Blood, 2014. PMID: None.
Jabbour E, Kantarjian, H, Thomas, D, Sasaki, K, Ravandi, F, Cortes, J, Pemmaraju, N, Kadia, T, Garris, R, Garcia-Manero, G, Borthakur, G, Wierda, O'Brien, S. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2014. PMID: None.
Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Dhanda R, Cain Z, Okoro T, Bolinder B, Jabbour E. Association Between Treatment Adherence and Response Among Patients With Chronic Myeloid Leukemia (CML) Receiving First-Line TKIs In The Community Setting. Blood, 2013. PMID: None.
Sasaki K, Kantarjian HM, Jabbour E, Quintas-Cardama A, Pierce S, Borthakur G, Kadia TM, Pemmaraju N, Ferrajoli A, O'Brien S, Cortes JE. Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction. Blood, 2013. PMID: None.
Nazha A, Kantarjian HM, Jabbour E, DiNardo CD, Borthakur G, Daver NG, Faderl SH, Ning J, Qiao W, Ravandi F, Kadia TM, Pierce SR, Cortes JE, Garcia-Manero G. Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. Blood, 2013. PMID: None.
Borthakur G, Verstovsek S, Jabbour E, Matthews J, Kadia TM, Daver N, Kantarjian HM, Cortes J. Eltrombopag For The Management Of Thrombocytopenia Associated With Tyrosine Kinase Therapy In Patients With Chronic Myeloid Leukemia and Myelofibrosis. Blood, 2013. PMID: None.
Cortes JE, Borthakur G, Pemmaraju N, Daver N, Quintas-Cardama A, Ravandi F, Gachimova E, Estrov Z, Jabbour E, O'Brien S, Kantarjian H. Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP). Blood, 2013. PMID: None.
Jabbour E, Kantarjian HM, Garcia-Manero G, Quintas-Cardama A, Cardena-Turanzas M, O'Brien S, Cortes JE, Jain N, Ravandi F, Kadia TM, Brandt M, Verstovsek S. Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy. Blood, 2013. PMID: None.
Jabbour E, Kantarjian HM, Qiao W, Strati P, Khan NF, Cortes JE, Hoehn D, Hu J, Obrien S, Bryan J, Prescott H, DiNardo CD, Daver N, Kadia TM, Garcia-Manero G. Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). Blood, 2013. PMID: None.
Jabbour E, Kantarjian HM, Ning J, Garcia-Manero G, Kadia TM, O'Brien S, Cortes JE, Hoehn D, Bryan J, Ravandi F, Verstovsek S. Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux). Blood, 2013. PMID: None.
Jabbour E, Garcia-Manero G, Xiao L, Najla AA, Mishra A, Padron E, Lancet JE, Bryan J, Prescott H, Steensma DP, Sekeres MA, Roboz GJ, List A, Kantarjian HM, Komrokji RS. Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. Blood, 2013. PMID: None.
Jabbour E, Hagop K, Thomas D, Garcia-Manero G, Hoehn D, Garris R, Faderl SH, Cortes JE, Kadia TM, Ravandi F, Verstovsek S, O'Brien S. Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2013. PMID: None.
Jabbour E, Kantarjian HM, Cameron Y, Ravandi F, Cortes JE, Garcia-Manero G, Ghanem H, Kadia TM, Faderl S, O'Brien S, Mathisen MS, Brandt M, Pemmaraju N, Thomas DA, Bass J, Borthakur AG. Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen. Blood, 2012. PMID: None.
Jabbour E, Kantarjian HM, Oran B, Ravandi F, Ghanem H, Khouri I, Garcia-Manero G, Mathisen MS, Bashir Q, Saliba RM, Khouri M, Pierce SA, Brandt M, Champlin RE, De Lima AM. Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities. Blood, 2012. PMID: None.
Jabbour E, Daver NG, Dong T, Kadia TM, O'Brien S, Cortes JE, Ravandi F, Pemmaraju N, Ghanem H, Faderl S, Borthakur G, Kantarjian HM, Garcia-Manero AG. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. Blood, 2012. PMID: None.
Komrokji RS, List AF, Khoury HJ, Lancet JE, Jabbour E, Foudray MD, Winski SL, Bell S, Rush SA, Maloney L, Ptaszynski AM, Kantarjian HM, Garcia-Manero G. Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes. Blood, 2011. PMID: None.
Jabbour E, Kantarjian H, Wang X, Abruzzo LV, Cornelison A, O’Brien S, Ravandi F, Kadia T, Borthakur G, Estrov Z, Cortes J, Garcia-Manero G. Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS). Blood, 2011. PMID: None.
Jabbour E, Kantarjian H, Quintas-Cardama A, Guilhot F, Zhu C, Hong J, Cain Z, Cortes J. Impact of Dose Reductions and Interruptions Due to Adverse Events (AEs) on Efficacy in Newly Diagnosed Chronic Myeloid Leukemia in ChronicPhase (CML-CP) Patients (pts) Receiving Either Dasatinib (D) or Imatinib(IM): Analysis of the DASISION Trial. Blood, 2011. PMID: None.
MTanaka, Jabbour E, Kantarjian H, Pierce S, Champlin R, Lima MD, Garcia-Manero G. Allogeneic Hematopoeitic Stem Cell Transplantation (AHSCT) Versus Hypomethylating Agents (HMA) in Patients (pts) with Myelodysplastic Syndrome (MDS): A Case-Control Study. Blood, 2011. PMID: None.
Boumber Y, Issa J, Jorgensen J, Faderl S, Castoro RJ, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). Blood, 2011. PMID: None.
Rytting M, Thomas D, Jabbour E, Franklin AR, Borthakur G, Faderl S, Schroeder K, Ravandi F, Garris R, O’Brien S, Kantarjian H. Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Modified Augmented Berlin-Frankfurt-Muenster (ABFM). Blood, 2011. PMID: None.
Mathisen M, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes J, Quintas-Cardama A. Clofarabine Does Not Impact Negatively the Outcomes of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Stem Cell Transplantation and Is Not Associated with Higher Liver Toxicity Rates Compared with Standard Chemotherapy. Blood, 2011. PMID: None.
Verstovsek S, Estrov Z, Cortes J, Thomas D, Borthakur G, Kadia T, Jabbour E, Pierce S, Kantarjian AH. The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study. Blood, 2011. PMID: None.
Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Godley L, Gabrail NY, Berdeja JG, Nadeem A, Stein K, Noble Y, Kassalow L, Kantarjian H. Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes. Blood, 2011. PMID: None.
Jabbour E, Kantarjian H, Wang X, Abruzzo L, Cornelison A, O’Brien S, Ravandi F, Kadia T, Borthakur G, Estrov Z, Cortes J, Garcia-Manero G. Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS). None, 2011. PMID: None.
Shoukier M, Kantarjian H, Jabbour E, Quintas-Cardama A, Estrov Z, Kadia T, Borthakur G, Garcia-Manero G, Kornblau SM, Burton E, O’Brien S, Cortes JE. Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts). Blood, 2011. PMID: None.
Lee H, Cortes J, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, MRios, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Kantarjian H. Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience. Blood, 2011. PMID: None.
Alattar M, Cortes J, O’Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Kantarjian H. Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy. Blood, 2011. PMID: None.
Thomas D, Kantarjian H, Faderl S, Wierda W, Jabbour E, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger J, Fayad L, Romaguera JE, Garris R, Cortes J, O’Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood, 2011. PMID: None.
Koller P, Kantarjian H, Koller C, Jabbour E, O’Brien S, Verstovsek S, Borthakur G, Estrov Z, Quintas-Cardama A, E Cortes AJ. Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI) Who Have a History of Prior Malignancies. Blood, 2011. PMID: None.
Naqvi, K, Kantarjian, H, Luthra, R, Jabbour E, O’Brien, S, Burton, E, Verstovsek, S, Ravandi, F, Wierda, W, Borthakur, G, Quintas-Cardama, A, Cortes, J. Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP). Blood, 2011. PMID: None.
Nazha A, Jabbour E, Cortes J, O’Brien S, Shan J, Garcia-Manero G, Quintas-Cardama A, Kantarjian H. EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC). Blood, 2011. PMID: None.
Cortes J, Garcia-Manero G, Ravandi F, Andreef M, Borthakur G, Jabbour E, Konopleva M, O’Brien S, Quintas-Cardama A, Verstovsek S, Wierda W, Kantarjian H. Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood, 2011. PMID: None.
Ravandi F, Faderl S, Cortes J, Garcia-Manero G, Jabbour E, Boone P, Kadia T, Borthakur G, Wierda W, Wetzler M, Venugopal P, Chiao J, Kantarjian H. Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML. Blood, 2011. PMID: None.
Kadia T, Ravandi F, Borthakur G, Jabbour E, Pierce S, Garcia-Manero G, Faderl S, Cortes J, Kantarjian H. Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder. Blood, 2011. PMID: None.
Shoukier M, Kantarjian H, Jabbour E, Quintas-Cardama A, Estrov Z, Kadia T, Borthakur G, Garcia-Manero G, Kornblau SM, Burton E, O’Brien S, Cortes J. Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML). Blood, 2011. PMID: None.
Alattar M, Kantarjian H, Jabbour E, Quintas-Cardama A, Burton E, Borthakur G, Verstovsek S, Wierda W, Konopleva M, Burger J, O’Brien S, Cortes AJ. Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML). Blood, 2011. PMID: None.
Garcia-Manero G, Estey EH, Jabbour E, Borthakur G, Kadia T, Naqvi K, Levine RL, Estrov Z, Quintas-Cardama A, Konopleva M, Faderl S, Tanaka M, Yang H, Ravandi F, Wierda W, Cortes J, Boone PA, Kantarjian H. Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. Blood, 2011. PMID: None.
Pemmaraju N, Kantarjian H, Luthra R, O’Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP). Blood, 2011. PMID: None.
Lee H, Kantarjian H, Thomas D, Faderl S, Koller C, Ferrajoli A, Jabbour E, Garris R, Kebriaei P, Champlin R, Borthakur G, Wierda W, Burger J, Cortes J, O’Brien S, Ravandi F. Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood, 2011. PMID: None.
Liu-Dumlao T, Kantarjian H, Quintas-Cardama A, Jabbour E, Burger J, Alvarado Y, Burton E, Trinh L, Ravandi F, Ferrajoli A, O’Brien S, Cortes AJ. Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML). Blood, 2011. PMID: None.
Malik A, Kantarjian H, Quintas-Cardama A, O’Brien S, Verstovsek S, Borthakur G, Ravandi F, Thomas D, Burton E, Jabbour E, Cortes AJ. Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome. Blood, 2011. PMID: None.
Pemmaraju N, Kantarjian H, Tanaka M, O’Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes AJ. Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy. Blood, 2011. PMID: None.
Liu-Dumlao T, O’Brien S, Cortes J, Thomas D, Faderl S, Jabbour E, Koller C, Garris R, Kebriaei P, Champlin R, Borthakur G, Ferrajoli A, Kantarjian H, Ravandi AF. Cmbination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB). Blood, 2011. PMID: None.
Quintás-Cardama A, Kim H, Shan J, Jabbour E, Faderl S, Wierda WG, Ravandi F, Kadia T, Wang SA, Pierce S, Kantarjian HM, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Blood, 2011. PMID: None.
Nazha A, Williams LA, Kantarjian HM, Ault PS, Garcia-Gonzalez A, Williams JL, Probst A, O'Brien S, Jabbour E, Quintas-Cardama A, Shi Q, Cleeland CS, Cortes JE. Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI). Blood, 2011. PMID: None.
Quintás-Cardama A, Kantarjian HM, Luthra R, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Garcia-Manero G, Faderl S, Knonpleva M, Wierda WG, Burton E, Cortes JE. Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP). Blood, 2011. PMID: None.
Knonpleva M, Borthakur G, Thall PF, Coveler A, Ravandi F, Jabbour E, Nguyen HQ, Benito JM, Gu Y, Wilson WR, Melink TJ, Kantarjian HM, Gutheil JC, Estey EH. Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection. Blood, 2011. PMID: None.
Ohanian M, Kantarjian HM, Quintas-Cardama A, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton EM, Trinh LX, Ferrajoli A, Jabbour E, Kadia T, Cortes JE. Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP). Blood, 2011. PMID: None.
Nazha A, Ravandi F, Kantarjian HM, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Knonpleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2011. PMID: None.
Daver N, Kantarjian HM, Garcia-Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger JA, Knonpleva M, Brandt M, Huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. Blood, 2011. PMID: None.
Garcia-Manero G, Tambaro FP, Bekele N, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia T, Knonpleva M, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce S, DeLima M, Kantarjian HM. Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). Blood, 2011. PMID: None.
O'Brien S, Thomas DA, Ohanian M, Jorgensen JL, Kebriaei P, Jabbour E, Rytting ME, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes JE, Fayad L, Tarnai R, Wang SA, Champlin R, Advani AS, Kantarjian HM. Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL). Blood, 2011. PMID: None.
Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau SM, Andreeff M, Garris R, Cortes JE, O'Brien S. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. Blood, 2011. PMID: None.
Borthakur G, Popplewell L, Kirschbaum M, Foran J, Kadia T, Jabbour E, Boyiadzis M, Verma A, Walter R, Wissel P, Xu L, Bauman J, Zhu J, Mazumdar J, Baccus M, Connor J, Cortes J, Kantarjian AH. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. JCO 29(15), 2011. PMID: None.
Jabbour E, O'Brien S, Thomas D, Ravandi F, York S, Kwari M, Faderl S, Kadia T, Wilson C, Tarnai R, Advani A, Garcia-Manero G, Cortes J, Kantarjian AH. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). JCO 29(15), 2011. PMID: None.
Shan J, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Cortes J, Kantarjian AH. Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure. JCO 29(15), 2011. PMID: None.
Quintas-Cardama A, Cortes J, Jabbour E, O'Brien S, Garcia-Manero G, Shan J, Ravandi F, Faderl S, Kadia T, Borthakur G, Kantarjian AH. Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. JCO 29(15), 2011. PMID: None.
Ghanem H, Kantarjian H, Garcia-Manero G, Ravandi F, Faderl S, Cortes J, Reyes A, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, and Jabbour E. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). JCO 29(15), 2011. PMID: None.
Ravandi F, Faderl S, Cortes J, Garcia-Manero G, Jabbour E, Boone P, Kadia T, Borthakur G, Wierda W, Chiao J, Kantarjian AH. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. JCO 29(15), 2011. PMID: None.
Malik A, Garcia-Manero G, Welch M, Kantarjian H, Stein K, Teng A, and Jabbour E. Retrospective analysis of prognostic factors associated with response and overall survival in patients with RAEB-t MDS treated with decitabine. JCO 29(15), 2011. PMID: None.
Cornelison M, Garcia-Manero G, Cortes J, Ravandi F, Kantarjian H, Stein K, Teng A, Jabbour E. Retrospective analysis of effects of dose modification and myelosuppression on response to decitabine and overall survival in patients with myelodysplastic syndromes. JCO 29(15), 2011. PMID: None.
Goldberg S, Bollu V, Morlock R, Niyazov A, Guo A, and Jabbour E. Association between chronic myeloid leukemia (CML) treatment responses and patient satisfaction, functioning, and quality of life (QOL): Patient survey results. JCO 29(15), 2011. PMID: None.
Gaballa S, Al-Kali A, Kantarjian H, Jabbour E, Quintas-Cardama A, Ayoubi M, Borthakur G, O'Brien S, Cortes J. Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs). JCO 28(15), 2010. PMID: None.
Fullmer A, Borthakur G, Kadia T, Garcia-Manero G, Jabbour E. Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine. JCO 28(15), 2010. PMID: None.
Saglio G, Cortes J, Schiffer C, Coutre P, Jabbour E, Bahceci E, Lambert A, Shah N. Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy. JCO 28(15), 2010. PMID: None.
Chen Y, Kantarjian H, Garcia-Manero G, Estrov Z, Konopleva M, Jabbour E, Kadia T, Williams B, George S, Borthakur AG. Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). JCO 28(15), 2010. PMID: None.
Borthakur G, Jabbour E, Wang X, Cortes J, Kashani F, Kadia T, Bass J, Brandt M, Kantarjian H. Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML). JCO 28(15), 2010. PMID: None.
Faderl S, Kashani F, Borthakur G, Kadia T, Jabbour E, Garcia-Manero G, Brandt M, Pierce S, Kantarjian H. Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison. JCO 28(15), 2010. PMID: None.
Dean A, Talpaz M, Kantarjian H, Faderl S, Jabbour E, Kashani F, O'Brien S, Rosenblum M, Cortes J. Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies. JCO 28(15), 2010. PMID: None.
Kadia T, Kashani F, O'Brien S, Cortes JE, Jabbour E, Borthakur G, Faderl S, Pierce S, Brandt M, Kantarjian H. Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). JCO 28(15), 2010. PMID: None.
Jabbour E, Kantarjian H, Garcia-Manero G, Kashani F, Borthakur G, Estrov Z, Gandhi V, Byrd A, Kwari M, Faderl S. A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS). JCO 28(15), 2010. PMID: None.
Cortes J, Borthakur G, O'Brien S, Jones D, Jabbour E, Ravandi F, Koller C, Walker B, Shan J, Kantarjian H. Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML - CP). Blood 114(22), 2009. PMID: None.
Garcia - Manero G, Tambaro F, Bekele B, Jabbour E, Ravandi F, Yang H, Borthakur G, Kadia T, Cortes J, Faderl S, Konopleva M, Pierce S, Burger J, Estrov E, O' Brien S, Thomas D, Newsome W, Kantarjian H. Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). Blood 114(22), 2009. PMID: None.
Santos F, Kantarjian H, Kadia T, Bivins C, O'Brien S, Ravandi F, Cortes J, Garcia - Manero G, Faderl S, Pierce S, Jabbour E. High Prevalence of FLT3 - ITD Mutations in Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Central Nervous System (CNS) Relapse. Blood 114(22), 2009. PMID: None.
Thomas D, Kantarjian H, Faderl S, Wierda W, Cortes J, Burger J, Ferrajoli A, Estrov E, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau S, Andreef M, Garris R, Keating M, O'Brien S. Chemoimmunotherapy with a Modified Hyper - CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B - Cell Acute Lymphpblastic Leukemia (ALL). Blood 114(22), 2009. PMID: None.
Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-manero G, Wierda W, Ravandi F, Borthakur, Rios M, Cortes J. Predicitive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure. Blood 114(22), 2009. PMID: None.
Verma D, Kantarjian H, Shan J, O'Brien S, Verma A, Jabbour E, Verstovsek S, Kadia TM, Rios M, Cortes J. Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?. Blood 114(22), 2009. PMID: None.
Garcia-Manero G, Couriel D, Tambaro F, Gabrial N, Nadeem A, Kadia TM, Jabbour E, Borthakur G, Faderl S, Newsome W, Yang H, Chen K, Stein K, Kantarjian H. A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Threes in Patients with Lower Risk Myelodysplastic Syndrome (MDS). Blood 114(22), 2009. PMID: None.
Santos F, Cortes J, koller K, Jabbour E. Combination Therapy with Tyrosine Kinase Inhibitors and Agents with Different Mechnisms of Actions Is Effective in a Patient with Chronic Myeloid Leukemia Harboring the T3151 BCR - ABL1 Mutation. Blood 114(22), 2009. PMID: None.
Dean A, Kantarjian H, O'Brien S, Rios M, Quintas - Cardama A, Jabbour E, Shan J, Cortes J. Causes of Death for Patients with Chronic Myeloid Leuekmia (CML) in Chronic Phase (CP) Treated with Imatinib. Blood 114(22), 2009. PMID: None.
Rios M, Jabbour E, Ravandi F, Kadia T, Estrov Z, Borthakur G, Buton E, Kantarjian H. Phase I Study of Bendamustine in Refractory Leukemia. Blood 114(22), 2009. PMID: None.
Tong W, Kadia T, Borthakur G, Jabbour E, Pierce S, Shan J, Cortes J, Ravandi F, Wierda W, Thomas D, Kantarjian H, Garcia - Manero G. Prognostic Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score. Blood 114(22):1469, 2009. PMID: None.
Hawk K, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Ccortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Garcia - Manero G. A Prognostic Model of Therapy - Related Myelodysplastic Syndrome. Blood 114(22):1460, 2009. PMID: None.
Kantarjian H, Jabbour E, Giles F, Bhalla K, Pinilla - Ibarz J, Larson R, Gattermann N, ottmann O, wang J, Woodman R, Baccarani M, D le Coutre P, Cortes J. Prognostic Factors for Progression - Free Survival in Patients with Imatinib - Resistant or - Intolerant Chronic Myeloid Leuekmia in Chronic Phase (CML - CP) Treated with Nilotinib Based On 24 Month Data. Blood 114(22):1278, 2009. PMID: None.
Jabbour E, Bahceci E, Zhu C, Lambert A, Cortes J. Predictors of Long - Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic - Phase Chronic Myeloid Leukemia (CML - CP). Blood 114(22):1278, 2009. PMID: None.
Jabbour E, Kantarjian H, Parikh S, Thomas D, Kadia T, Garcia - Manero G, Borthakur G, Pierce S, Brandt M, Cortes J, Verstovsek S. Comparison of Thalidomide and Lenalidomide foe the Treatment of Patients (pts) with Myelofibrosis (MF). Blood 114(22), 2009. PMID: None.
Santos F, Schlette E, Kantarjian H, Sargent R, Garcia - Manero G, Verstovsek S, Kadia T, Jabbour E, Pierce S, Borthakur G. Myelodysplastic Syndrome with Fibrosis: Experience of a Single - Institution with 139 Patients. Blood 22(114), 2009. PMID: None.
Kadia T, Estrov Z, Ravandi F, Koller C, Borthakur G, Jabbour E, Faderl S, Pierce S, Cortes J, Kantarjian H, Garcia - manero G. Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodyplastic Syndrome (MDS) Treated on Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid. Blood 114(22), 2009. PMID: None.
Parikh S, Kantarjian H, Garcia - Manero G, Jabbour E, Kadia T, Ravandi F, Ferrajoli A, Estrov Z, Feliu J, Faderl S. Clofarabine plus Low - Dose Cytarabine Induction Followed by Consolidation with Clofarabine plus Low - Dose Cytarabine Alternating with Decitabine as Frontline therapy for Patients (pts) with Acute Myeloid Leukemia (AML) > 60 years (yrs). Blood 114(22), 2009. PMID: None.
Garcia- Manero G, Khoury H, Borthakur G, Ravandi F, Kadia T, Estrov E, Jabbour E, Foudray M, Arellano S, Langston A, Bryan B, Rush S, Freeman B, Simmons H, Ptaszynski M, Kantarjian H. A Phase I Dose - Escalation Study of the Novel KSP Inhibitor ARRY - 520 in Advanced Leukemias. Blood 114(22), 2009. PMID: None.
Ravandi F, Kantarjian H, Cortes J, Thomas D, Faderl S, Jones D, Jabbour E, Koller C, Dara S, Garris R, Kebriaei P, Borthakur G, Ferrajoli A, O'Brien S. Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML - LB). Blood 114(22), 2009. PMID: None.
Rytting M, Thomas D, Franklin A, Jabbour E, Wierda W, Faderl S, Wells R, kadia T, Ravandi F, Ferrajoli A, Cortes J, O'Brien S, Kantarjian H. Pediatric - Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia. Blood 114(22), 2009. PMID: None.
Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 2009. e-Pub 2009. PMID: 19567878.
Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. Mayo Clin Proc 84(2):161-9, 2009. PMID: 19181650.
Jabbour E. Long-term efficacy of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in patients (pts) with advanced Chronic Myeloid Leukemia (CML) post imatinib failure. Blood, 2008. PMID: None.
Jabbour E. Outcome of patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) post decitabine failure. Blood, 2008. PMID: None.
Jabbour E. Clinical characteristics and outcome of patients (pts) with V299L BCR-ABL kinase domain (kd) mutation after therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 2008. PMID: None.
Jabbour E. Increase in the incidence of Secondary Acute Myeloid Leukemia (2-AML): A single institution experience over 20 years. Blood, 2008. PMID: None.
Jabbour E. Results of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for advanced Chronic Myeloid Leukemia (CML) patients (pts) who failed Tyrosine Kinase Inhibitors (TKIs) after developing BCR-ABL kinase domain (kd) mutations. Blood, 2008. PMID: None.
Jabbour E. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or accerlerated phase (CML-AP). Blood, 2008. PMID: None.
Jabbour E. Combination of the hyperCVAD regimen with dasatinib is effective in patients with relapsed Philadelphia Chromosome (Ph) positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). Blood, 2008. PMID: None.
Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-42. e-Pub 2008. PMID: 18818391.
Jabbour E. Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) after Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 2007. PMID: None.
Jabbour E. Event-Free Survival in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure is Dependent on the In Vitro Sensitivity of BCR-ABL Kinase Domain (KD) Mutations. Blood, 2007. PMID: None.
Jabbour E. Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs). Blood, 2007. PMID: None.
Jabbour E. In Vitro Response to Sequential Tyrosine Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) Modeled Based on In Vitro Properties of Particular BCR-ABL Kinase Domain (KD) Mutations. Blood, 2007. PMID: None.
Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer Journal 6:357-65, 2007. PMID: None.
Jabbour E. Characteristics and Outcome of Patients with Chronic Myeloid Leukemia (CML) and T315I Mutation Following Failure of Imatinib Mesylate Therapy. Blood, 2007. PMID: None.
Jabbour E. Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML). Blood, 2007. PMID: None.
DeLima M, Champlin RE, Thall PF, Wang X, TGrd M, Cook JD, McCormick G, Qazibash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Anderson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia, 2007. e-Pub 2007. PMID: None.
Jabbour E, Cortes J, Kantarjian H, Giralt S, Champlin R, and de Lima M. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity. Biology of Blood and Marrow Transplantation 13:91, 2007. PMID: None.
Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, and de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108:1421-1423, 2006. PMID: None.
Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, and Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at MD Anderson Cancer Center. Blood 107:880-884, 2006. PMID: None.
Jabbour E, Kantarjian H, Giles F, O'Brien S, and Cortes J. . Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib. Blood 108:616A, 2006. PMID: None.
Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O'Brien S, Verstovsek S, Garcia-Manero G, Newman BA, Giles F, Issa JP, and Kantarjian HM. Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy. Blood 108:157A, 2006. PMID: None.
Jabbour E, Jones D, Kantarjian H, O'Brien S, Garcia-Manero G, Giles F, Wierda W, and Cortes J. Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI). Blood 108:225A, 2006. PMID: None.
Giles F, Borthakur G, Ravandi F, Verstovsek S, Pierce S, Jabbour E Cortes J, and Kantajian H. Comorbidity scoring using the hematopoetic cell transplantation comorbidity index (HCTCI) is predictive of early death rate and event free survival (EFS) in patients over 60 years of age receiving induction therapy for acute mycloid leukemia (AML). Blood 108:559A, 2006. PMID: None.
Jabbour E, Hosing C, Pro B, Khouri I, Younes A, Champlin R, and Fayad L. Pre-transplant positive pet/gallium scans predict poor outcome in relapsed/refractory hodgkin lymphoma (HL). Biology of Blood and Marrow Transplantation 12:114-115, 2006. PMID: None.
Jabbour E, Cortes J, de Lima M, Anderson B, Giralt S, Kantarjian H, and Champlin R. Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing Bcr-Abl kinase mutations with allogeneic stem cell transplantation (ASCT). Biology of Blood and Marrow Transplantation 12:18, 2006. PMID: None.
Jabbour E, Cortes J, Kantarjian H, Giralt S, Giles F, Anderson BS, Champlin R, and de Lima M. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity. Blood 108:407B, 2006. PMID: None.
Jabbour E, Kantarjian H, Koller CA, Faderl S, Ferrajoli A, Richie MA, Garcia-Manero G, Cortes J, Estrov Z, Ravandi-Kashani F, Giles F, and Verstovsek S. PEG-Intron therapy in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPD): Final result of a phase II study. Blood 108:1039A, 2006. PMID: None.
Jabbour E, O'Brien S, Ravandi-Kashani F, Cortes J, Borthakur G, Verstovsek S, Garcia-Manero G, Giles F, Zanoria L, Davisson J, Issa JP, and Kantarjian HM. Decitabine induces high response rates in patients with chronic myelomonocytic leukemia (CMML). Blood 108:750A, 2006. PMID: None.
Jabbour E, Kantarjian HM, Cortes J, Wierda WG, Ferrajoli A, Faderl S, O'Brien S, Ravandi-Kashani F, Verstovsek S, Garcia-Manero G, Davisson J, Giles F, Shan J, and Issa JP. Survival benefit with decitabine compared to historical experience with intensive chemotherapy in patients with higher risk myelodysplastic syndrome (MDS). Blood 108:749A-750A, 2006. PMID: None.
Jabbour E, Kantarjian H, Jones D, Giles F, Borthakur G, O'Brien S, and Cortes J. Clinical characteristics and outcome of patients (pts) with T315I mutation after imatinib failure. Blood 108:621A, 2006. PMID: None.
Jabbour E, Cortes J, Giles F, O'Brien S, Letvak L, and Kantarjian H. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Blood 108:616A, 2006. PMID: None.
Atallah E, Durand JB, Kantarjian H, Jabbour E, O'Brien S, Rios MB, and Cortes J. Congestive heart failure is a rare event in patients (pts) receiving imatinib therapy. Blood 108:609A, 2006. PMID: None.
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, and Issa JP. Phase 1/2 study of the combination of 5-aza-2 '-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279, 2006. PMID: None.
Champlin RE, Jabbour E, Cortes J, Kantarjian H, Anderson BS, Giralt S, and de Lima M. Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing BCR-ABL kinase mutations with allogeneic stem cell transplantation (ASCT). Journal of Clinical Oncology 24:348S, 2006. PMID: None.
Jabbour E, Kantarjian H, Abruzzo L, Giles F, Rios MB, and Cortes J. Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during novel tyrosine kinase inhibitors (NTKI) therapy in patients (pts) with chronic myeloid leukemia (CML) after imatinib-failure. Blood 108:600A, 2006. PMID: None.
Jabbour E, Kantarjian H, Ravandi-Kashani F, Garcia-Manero G, O'Brien S, and Cortes J. Clinical significance of loss of chromosome Y (-Y) in patients with chronic myeloid leukemia (CML): Is it clonal evolution?. Blood 108:600A, 2006. PMID: None.
Jabbour E, Kantarjian H, O'Brien S, Verstovsek S, Garcia-Manero G, Rios MB, and Cortes J. Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during imatinib mesylate (IM) therapy in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. Blood 106:317A-318A, 2005. PMID: None.
Jabbour E, Cortes J, Talpaz M, Jones D, O'Brien S, Nicaise C, and Kantarjian H. Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) with chronic myeloid leukemia (CML) treated at MD Anderson cancer center (MDACC). Blood 106:318A, 2005. PMID: None.
Jabbour E, Kantarjian H, Talpaz M, Jones D, O'Brien S, Giles F, Garcia-Manero G, Ravandi F, Faderl S, Verstovsek S, Rios MB, and Cortes J. Outcome of salvage therapy in patients (pts) with chronic myeloid leukemia (CML) who failed imatinib after developing BCR-ABL kinase mutation. Blood 106:318A, 2005. PMID: None.
Jabbour E, Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Garcia-Manero G, Wierda W, Pierce S, Shan JQ, and Estey E. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome. Blood 106:525A, 2005. PMID: None.
Jabbour E, Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan JQ, Plunkett W, Keating M, and Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Blood 106:710A, 2005. PMID: None.
Jabbour E, Hosing C, Pro B, Khouri I, and Fayad L. Positive pre-transplant PET/GA67 scan (GA) predicts poor outcome in refractory and relapse Hodgkin's lymphoma (HL). Annals of Oncology 16:121, 2005. PMID: None.
Jabbour E, Hosing C, Pro B, Champlin R, Khouri I, Romaguera J, and Fayad LE. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin's lymphoma (HL). Journal of Clinical Oncology 23:562S, 2005. PMID: None.
Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, Koller C, O'Brien S, Plunkett W, Garcia-Manero G, Jackson E, Kantarjian H, and Andreeff M. 2 chlorodeoxyadenosine (2-CdA) and cytarabine (ara-C) combination is effective and safe in idiopathic hypereosinophilic syndrome (HES). Blood 104:274B, 2004. PMID: None.
Jabbour E, Kantarjian H, Jones D, O'Brien S, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, and Cortes J. Long-term incidence and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate - P-loop mutations are not associated with worse outcome. Blood 104:288A, 2004. PMID: None.
Oki Y, Jabbour E, Kantarjian H, Estey E, Cortes JE, Faderl S, Pierce S, Zhou X, Bekele BN, and Garcia-Manero G. Intracranial hemorrhage (ICH) in patients (pts) with newly diagnosed leukemia: Incidence and effect on outcome. Blood 104:216B, 2004. PMID: None.
Jabbour E, Kantarjian H, Verstovsek S, Jones D, O'Brien S, Luthra R, Ravandi-Kashani F, Wierda W, Giles F, Rios MB, and Cortes J. Imatinib mesylate for patients (pts) with hypereosinophilic syndrome (HES) and systemic mastocytosis (SM): A phase II trial. Blood 104:271B, 2004. PMID: None.
Jabbour E, Peslin N, Sebban C, Patte C, Gargi T, Ferme C, Bourhis JH, Vantelon JM, Arnaud P, and Vincent R. High survival rate with modified LMT-81 regimen in lymphoblastic lymphoma (LL). Blood 102:405A, 2003. PMID: None.
Jabbour E, Peslin N, Arnaud P, Carde P, Vantelon JM, Bocaccio C, Ferme C, Bourhis JH, and Vincent R. Prognostic value of IPI assessed before high dose salvage therapy in chemosensitive relapsed aggressive lymphomas (NHL). Blood 102:481B, 2003. PMID: None.

Book Chapters

Kantarjian, HM, Jabbour, EJ, O'Brien, S. Chronic myelogenous leukemia, 83-97, 2024.
Paul, S, Rausch, CR, Kantarjian, HM, Jabbour, EJ. Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia, 205-218, 2021.
Chew, S, Short, NJ, Kantarjian, HM, Jabbour, EJ. Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, 219-233, 2021.
Lovell, A, Jabbour, EJ, Cortes, JE, Kantarjian, HM. CML Therapy, 61-76, 2021.
Mackey, MC, Chew, S, Kantarjian, HM, Jabbour, EJ. Frontline Therapy of Newly Diagnosed Acute Lymphoblastic Leukemia, 169-184, 2021.
Jammal, N, Chew, S, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Management of Relapsed/Refractory Acute Myeloid Leukemia, 89-109, 2021.
Jabbour E, Faderl S, Kantarjian H. Adult acute lymphocytic leukemia. In: The MD Anderson manual of clinical oncology. Kantarjian H, Koller C, Wolff R (Eds.),. None. McGraw-Hill, 2016.
Jabbour E, Cortes J, Kantarjian H. Targeted therapy in cancer: chronic myeloid leukemia. In: Targeted therapy in cancer. Razelle Kurzrock and Maurie Markman (Eds),. None. The Humana Press, 2016.
Jabbour E, Cortes J, Kantarjian H. Chronic myeloid leukemia: new targeted therapies. In: Recent advances in the chronic myeloproliferative disorders. Tariq Mughal and John Goldman (Eds),. None. Taylor and Francis, 2015.
Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia: frontline-current treatment options. In: Recent advances in the chronic myeloproliferative disorders. Tariq Mughal and John Goldman (Eds),. None. Taylor and Francis, 2013.
Jabbour E, Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: Leukemia. None. Demos Medical Publishing, 239-58, 2011.
Jabbour E, Parikh S, Kantarjian H, Cortes J. Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment. In: Chronic Myelogenous Leukemia. 5. Elsevier Inc, 981-96, 2011.
Jabbour E, Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: Management of Hematologic Maligniancies. None. Cambridge University Press, 68-80, 2011.
Jabbour E, Fullmer A, Faderl S. Acute Lymphoblastic Leukemia. In: The MD Anderson Manual of Medical Oncology. None. McGraw-Hill, 3-14, 2011.
Parikh S, Jabbour E, Koller C. Adult Acute Myeloid Leukemia. In: The MD Anderson Manual of Medical Oncology. None. McGraw-Hill, 15-32, 2011.
Pemmaraju N, Parikh S, Jabbour E, Kantarjian E, Cortes J. Chronic Myeloid Leukemia. In: The MD Anderson Manual of Medical Oncology. None. McGraw-Hill, 53-74, 2011.
Jabbour E, Cortes J, Kantarjian H. Standard Management of Patients with Chronic Myeloid Leukemia. In: Advances in Malignant Hematology. None. Blackwell Publishing Ltd, 71-85, 2011.
Fullmer A, Kantarjian H, Jabbour E. Novel and Targeted Therapies in Leukemia. In: Leukemia. None. Demos Medical Publishing, 389-410, 2011.
Sweany S, Jabbour E. Treatment of Myeloproliferative Neoplasms. In: Neoplastic Hematopathology, Experimental and Clinical Approaches. None. Humana Press, 213-22, 2010.
Jabbour E, Estey E, Kantarjian HM. Adult acute Myeloid Leukemia. In: Mayo Clin Proc. 2. None, 15-32, 2006.
Jabbour E, Borthakur G, Bueso-Ramos C, Kantarjian H, Faderl S. Acute Lymphoblastic Leukemia. In: MD Anderson Manual of Medical Oncology. None. McGraw-Hill, 3-18, 2006.

Letters to the Editor

Zhou, T, Curry, CV, Khanlari, M, Shi, M, Cui, W, Peker, D, Chen, W, Wang, E, Gao, J, Shen, Q, Xie, W, Jelloul, FZ, King, RL, Yuan, J, Wang, X, Zhao, C, Obiorah, IE, Courville, E, Nomura, E, Cherian, S, Xu, ML, Burack, WR, Liu, Hx, Jabbour, EJ, Takahashi, K, Wang, W, Wang, SA, Khoury, J, Medeiros, LJ, Hu, S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood cancer journal 14, 2024.
Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, Kadia, TM, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14, 2024.
Jen WY, Jabbour E, Short NJ, Issa GC, Haddad FG, Jain N, Pemmaraju N, Daver NG, Masarova L, Borthakur G, Chien K, Garris R, Kantarjian HM. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol 99: 2229-2232, 2024.
Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 147: 107602, 2024.
Mustafayev K, Yepez Guevara E, DiNardo CD, Jabbour E, Ghayas IC, Ratan R, Pemmaraju N, Torres HA. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leuk Res 147: 107597, 2024.
Gibson A, Nunez C, Robusto L, Kammerer B, Garcia M, Roth M, Sheth R, Tewari P, Hittle A, Toepfer L, Torres R, Short NJ, Jabbour E, Jain N, Cuglievan B, McCall D. Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica 109: 3042-3047, 2024.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour E, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis. Haematologica 109: 2660-2664, 2024.
Haddad FG, Sasaki K, Issa GC, Jabbour E, Kantarjian H. The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. American journal of hematology 99: 1175-1176, 2024.
Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour E, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. American journal of hematology 99: 792-796, 2024.
Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica 109: 293-297, 2024.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour E, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13: 148, 2023.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. American journal of hematology 98: E281-E284, 2023.
Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leukemia Research 127: 107044, 2023.
Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, Daver N, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Advances 7: 828-831, 2023.
Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, Garcia-Manero G, Short NJ, Ravandi F, Jabbour E. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. American journal of hematology 98: E11-E14, 2023.
Short N, Macaron W, Kadia T, Dinardo C, Issa G, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel P, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas H, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian H, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. American journal of hematology 97: E408-E411, 2022.
Nichols ED, Jabbour E, Jammal N, Chew S, Bryan J, Issa G, Garcia-Manero G, Sasaki K, DiPippo A, Kantarjian H. Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. American journal of hematology 97: E350-E352, 2022.
Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. American journal of hematology 97: E201-E204, 2022.
Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, Foran JM, Granroth GL, Olteanu H, Kadia T, Tefferi A, Pemmaraju N. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. American journal of hematology 97: E62-E67, 2022.
Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S, Jabbour E, Kadia T, DiNardo C, Garcia-Manero G, Qazilbash M, Konopleva M, Kantarjian H. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood 138: 1373-1377, 2021.
Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia. American journal of hematology 96: E379-E383, 2021.
Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. American journal of hematology 96: E275-E279, 2021.
Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). American journal of hematology 96: E246-E249, 2021.
Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone marrow transplantation 56: 1746-1749, 2021.
Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. American journal of hematology 96: E229-E232, 2021.
Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood cancer journal 11: 52, 2021.
Koller PB, Zhang H, Kantarjian H, Jabbour E, Pierce S, Gocho Y, Roberts KG, Yang W, Mullighan CG, Yang J, Konopleva M, Jain N. GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults. American journal of hematology 96: E71-E74, 2021.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients. Blood cancer journal 11: 60, 2021.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106: 894-898, 2021.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American journal of hematology 96: E50-E53, 2021.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood cancer journal 11: 25, 2021.
Cassaday RD, Marks DI, DeAngelo DJ, Jabbour EJ, Advani AS, O'Brien S, Wang T, Neuhof A, Vandendries E, Kantarjian HM, Stock W, Stelljes M. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol 191: e77-e81, 2020.
Pandey RK, DiPippo A, Kadia T, Pemmaraju N, Workeneh BT, Jabbour E, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma 61: 2775-2777, 2020.
Malek AE, Raad II, Jabbour E. Cancer and COVID-19. Lancet 396: 1066-1067, 2020.
Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol 95: E245-E247, 2020.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34: 2489-2492, 2020.
Jabbour E, Stelljes M, Advani AS, DeAngelo DJ, Gokbuget N, Marks DI, Stock W, O'Brien S, Cassaday RD, Wang T, Neuhof A, Vandendries E, Kantarjian H. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma 61: 2012-2015, 2020.

Less

Grant & Contract Support

Title:	2021-0840 Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in
Funding Source:	Amgen
Role:	PI

Title:	LCK-targeted Therapy in T cell Acute Lymphoblastic Leukemia
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I

Title:	2021-0319 A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia
Funding Source:	JANSSEN RESEARCH AND DEVELOPMENT LLC
Role:	PI

Title:	Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Funding Source:	University of Alabama - Birmingham
Role:	Co-PI

Title:	2020-0135 Ph1b Blinatumomab + AMG 404 in R/R B-ALL
Funding Source:	Amgen
Role:	PI

Title:	2020-0133 Ph1b SQ Blinatumomab in R/R B-ALL
Funding Source:	Amgen
Role:	PI

Title:	2014-0845Hyper-CVAD + Blinatumomab ALL
Funding Source:	Pfizer
Role:	PI

Title:	2019-0705 Ph1b HQP1351 in Refractory CML
Funding Source:	Ascentage
Role:	PI

Title:	2016-0629 Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Funding Source:	Abbvie
Role:	PI

Title:	2018-0434 Reduce Intensity Chemo + Ponatinib vs. Reduce Intensity Chemo + Imatinib
Funding Source:	Takeda
Role:	PI

Title:	2010-0991 mHCVD + Inotuzumab + /- Rituximab + Blinatumomab
Funding Source:	St. Jude
Role:	PI

Title:	2010-0991 mHCVD + Inotuzumab + /- Rituximab + Blinatumomab
Funding Source:	Amgen
Role:	PI

Title:	2017-0679 A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed Acute Lymphoblastic Leukemia
Funding Source:	Abbvie
Role:	PI

Title:	2017-0127 Chemo + blinatumomab in ALL
Funding Source:	Amgen
Role:	PI

Title:	2016-0402 Low Intensity Chemotherapy + Ponatinib
Funding Source:	Takeda
Role:	PI

Title:	2016-0792 Blinatumomab + Ponatinib with Ph- and/or BCR-ABL + ALL
Funding Source:	Takeda
Role:	PI

Title:	2015-0921 Phase II Study of Inotuzumab Ozogamicin in Patients with B-cell Lineage Acute Lymphocytic Leukemia with Positive Minimal Residual Disease
Funding Source:	Pfizer
Role:	PI

Title:	2014-0845 A Phase II study of the hyper-CVAD regimen in sequential combination with blinatumomab as ironline therapy for adults with B-Cell Lineage Acute Lymphocytic Leukemia
Funding Source:	Amgen
Role:	PI

Title:	2014-0844 Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocyte Leukemia with Positive Minimal Residual Disease After Frontline Therapy
Funding Source:	Amgen
Role:	PI

Title:	2014-0437 Bosutinib vs Imatinib in CP CML
Funding Source:	Pfizer
Role:	PI

Title:	2012-0669 Ponatinib
Funding Source:	ARIAD Pharmaceuticals, Inc
Role:	PI

Title:	2008 -0598 Hyper-CVAD + Loposomal Vincristine in ALL
Funding Source:	Talon Therapeutics
Role:	PI

Title:	2011-0030 Phase II study of Combination Hyper-CVAD and Ponatinib in Patients with Philadelphia (PH) Chromosome Positive and /or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Funding Source:	Ariad Pharmaceuticals
Role:	PI

Title:	2010-0991 mHCVD + Inotuzumab + /- Rituximab + Blinatumomab
Funding Source:	Pfizer
Role:	PI

Title:	Phase I-II Study of Low-Dose Azacitidine (Vidaza) in Patients With Chronic Myeloid Leukemia who Have Minimal Residual Disease While Receiving Therapy with Tyrosine Kinase Inhibitors
Funding Source:	MDACC IRG
Role:	PI

Title:	2022-0427 A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
Funding Source:	JANSSEN RESEARCH AND DEVELOPMENT LLC
Role:	PI

Title:	PA19-0112 Proposal for analysis of Ph-Like ALL from the BLINCYTO ISS sample cohort
Funding Source:	AMGEN INC
Role:	PI

Title:	2013-0870 "A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) post Hypomethylating Agent (HMA) Failure"
Funding Source:	Teva
Role:	PI

Title:	2013-0812: A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Funding Source:	Teva
Role:	PI

Title:	2012-0598: A Randomized, Double-blind, Placebo-controlled, Two-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 Myelodysplastic Syndrome Patients Based on International Prognostic Scoring System
Funding Source:	Onconova
Role:	PI

Title:	Wintermann Foundation Grant
Funding Source:	Wintermann Foundation Grant
Role:	Project Leader

Title:	2010-0708: Phase II Study of the Hyper - CVAD Regimen in Combination with Ofatumumab as Frontline Therapy for Adults with CD-20 positive Acute Lymphoblastic Leukemia
Funding Source:	GlaxoSmithKline
Role:	PI

Title:	2010-0244: A Phase 1 Dose - Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Advanced Hematological Malignancies
Funding Source:	Tragara
Role:	PI

Title:	2020-0435 Ph1b/2 AUTO1-AL1 (CAR-T CD19) in R/R B-ALL or Ph+ ALL (intolerant/failed TKIs)
Funding Source:	Autolus
Role:	PI

Title:	Amgen 2018773348
Funding Source:	Amgen Inc
Role:	PI

CV information above last modified October 31, 2024

Elias Jabbour, M.D.

About Dr. Jabbour

In the News

ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia

ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias

Maintenance therapy for chronic leukemia: What patients should know

Chronic versus acute leukemia: Different diagnoses, different treatments

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Related Links

Leukemia

Leukemia Center

Leukemia Department

Cancer Medicine Division

Help #EndCancer

Elias Jabbour, M.D.

About Dr. Jabbour

In the News

ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia

ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias

Maintenance therapy for chronic leukemia: What patients should know

Chronic versus acute leukemia: Different diagnoses, different treatments

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Leukemia

Leukemia Center

Leukemia Department

Cancer Medicine Division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer